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Abstract 
 
Skeletal muscle (SM) is the largest organ in the human body and represents 
approximately 40% of the total body weight.  Maintenance of SM mass and integrity is 
dependent on the delivery and removal of essential metabolic products as well as the 
dynamic balance between protein synthesis and degradation.  The health and maintenance 
of skeletal muscle in cancer patients is of particular importance, as the significant loss of 
muscular mass is an indication of cachexia, a serious life-threatening condition.  
Doxorubicin (DOX) is a broad-spectrum anti-cancer chemotherapeutic and remains one of 
the most widely used chemotherapeutic agents for the treatment of solid tumors and 
hematological malignancies.  The clinical use of DOX is limited by a well described dose-
dependent and cumulative cardiotoxic side effect.  The majority of DOX-related research 
remains focused on reducing cardiotoxicity while little is known of the effect of the drug 
on SM.  Therefore, the purpose of the thesis was to study the effects of DOX chemotherapy 
on SM. 
Study 1.  The purpose of Study 1 was to examine the accumulation of doxorubicin (DOX) 
and its metabolite doxorubicinol (DOXol) in skeletal muscle of the rat up to 8 days after 
the administration of a 1.5 or 4.5 mg/kg i.p. dose.  Subsequent to either dose, DOX and 
DOXol were observed in skeletal muscle throughout the length of the experiment.  
Interestingly an efflux of DOX was observed after 96 hrs, followed by an apparent re-
uptake of the drug which coincided with a spike and rapid decrease of plasma DOX 
concentrations.  The interstitial space within the muscle did not appear to play a significant 
rate limiting compartment for the uptake or release of DOX or DOXol from the tissue to 
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the circulation.  Furthermore, there was no evidence that DOX preferentially accumulated 
in a specific muscle group with either dose.   
Study 2.  Study 2 examined intracellular and interstitial nitric oxide (NO) concentrations in 
the SM following the administration of DOX.  A single dose of 1.5 or 4.5 mg/kg was 
administered intraperitoneally to male Sprague-Dawley rats and interstitial (IS) and 
intracellular (IC) NO was quantified every 24 up to 192 hrs. post injection.  There was no 
significant difference in IC NO following the injection of 1.5 mg/kg DOX when compared 
to control, however the administration of 4.5 mg/kg DOX resulted in lower (P<0.05) 
concentrations of NO in the IC.  Interestingly, a consistently higher (P<0.05) concentration 
of NO in the IS was established following the administration of 1.5 mg/kg compared to 
control while no significant changes in IS NO resulted from the administration of the 4.5 
mg/kg dose.  The fluctuation of IS and IC NO were not a result of substrate availability as 
arginine concentrations remained stable throughout the experiment. 
Study 3.  The purpose of Study 3 was to examine the effect of DOX administration on IC, 
IS and vascular concentrations of amino acids (AA) in SM of the rat up to 8 days after the 
administration of a 1.5 or 4.5 mg/kg i.p. dose.  Intracellular total amino acids (TAA), 
essential amino acids (EAA) and branched-chain amino acids (BCAA) were significantly 
increased in each muscle group analyzed, following the 1.5 and 4.5 mg/kg doses compared 
to control.  In the plasma, TAA were significantly increased compared to control where 
greater (P>0.05) concentrations were observed following the 1.5 mg/kg dose compared to 
the 4.5 mg/kg dose.  Compared to control, the 1.5 mg/kg dose resulted in an increase 
(P<0.05) in interstitial TAA whereas the 4.5 mg/kg resulted in a sustained decrease 
(P<0.05). 
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These data represent the first concurrent investigation into the accumulation of DOX in the 
IC, IS and vascular spaces as well as the resulting effects on NO and AA concentrations in 
these communicating compartments.  Overall, SM plays an important factor in the 
availability and metabolism of DOX and the effect of DOX on SM may play a more 
significant role in the therapeutic impact of DOX than previously considered.  This thesis 
provides a substantial foundation for future studies focused on reducing DOX-induced 
skeletal muscle damage. 
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CHAPTER I 
 
1.  Literature Review 
1.1  Skeletal Muscle Energetics 
Skeletal muscle represents the largest organ in the human body, consisting of 
approximately 40% of the total body weight.  The mechanical role of skeletal muscle is 
essential to life and muscle contraction is dependent on the breakdown of adenosine 
triphosphate (ATP) by adenosine triphosphatase (ATPase) and the resulting release of free 
energy in form of inorganic phosphate (Pi).  The contribution of three well established 
energy systems are primarily responsible for the replenishment of ATP stores (Baker, 
McCormick, & Robergs, 2010; Westerblad, Bruton, & Katz, 2010).  The phosphagen 
system rapidly regenerates ATP by way of creatine kinase (CK), adenylate kinase and 
adenosine monophosphate (AMP) deaminase.  The reversible enzymatic activity of CK 
allows for the rapid breakdown or synthesis of phosphocreatine during energy expenditure 
or storage, respectively.  Additionally, adenylate kinase is a phosphotransferase that 
catalyzes a reaction that converts two adenosine diphosphate (ADP) molecules into a single 
ATP and AMP molecule.  Equally important to the production of ATP is that of AMP, which 
activates phosphorylase and phosphofructokinase, two key enzymes in the initial phase of 
the glycolytic pathway.  The glycolytic pathway regulates carbohydrate metabolism by 
catabolizing glycogen stores into glucose and promoting the uptake of glucose from the 
blood, (Pilegaard et al., 1999) producing a net yield of ATP as well as pyruvate and 
nicotinamide adenine dinucleotide (NADH).  In the presence of oxygen, pyruvate is 
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shuttled to the mitochondria where it enters the TCA cycle and is oxidized to generate ATP.  
Similarly, in an aerobic state, NADH enters the mitochondria where it plays a key role in 
the electron transport chain.  In the absence of sufficient oxygen, NADH is utilized by 
lactate dehydrogenase in the reaction to reduce pyruvate to lactate.  Lactate reduction or 
removal from the cytosol into circulation prevents product inhibition of the glycolytic 
pathway, thus allowing the progression of glycolysis.  Fatty acids, from intramuscular 
stores or deriving from the circulation, are also oxidized in the mitochondria following 
acyl-CoA synthase breakdown to Fatty-acyl CoA and subsequent metabolism by beta-
oxidation and the TCA cycle to generate ATP.  Central in the ability of skeletal muscle to 
produce energy from either aforementioned system is the delivery of oxygen, glucose and 
fatty acids and the removal of metabolic products such as lactate.  As such, the vascular 
perfusion of the tissue is essential in its ability to produce energy and meet energetic 
demand.  
 
1.2  Mediation of local perfusion: Nitric Oxide 
Local vasoregulation in skeletal muscle is highly complex and involves several 
vasoactive compounds which function synergistically on the smooth muscle cells 
underlying the vascular endothelium to regulate the local vascular tone.  The local 
perfusion of myocytes is equally important for the delivery of nutrients required for normal 
cell function, as it is for the removal of unwanted and potentially toxic metabolic 
byproducts.  During any given physiological state, the local vascular tone in skeletal muscle 
is determined by the balance between competing intrinsic vasoconstrictive and 
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vasodilatory factors.  Nitric oxide (NO) is a potent gaseous vasodilatory molecule 
endogenously produced in skeletal muscle (Archer et al., 1994; Calabrese et al., 2007; 
Riddell & Owen, 1999).  In the presence of L-arginine (Arg), NADPH and molecular 
oxygen, NO is enzymatically produced by three nitric oxide synthase isoforms named after 
the cells in which they were originally purified.  Endothelial NOS (eNOS) and neuronal 
NOS (nNOS) are constitutive calcium and calmodulin-dependent isoforms, whereas the 
macrophage or calcium calmodulin-independent isoform NOS is otherwise known as 
inducible NOS (iNOS) (Forstermann & Sessa, 2012; Stamler & Meissner, 2001).  The 
constitutive isoforms of NOS (eNOS, nNOS) are activated by the influx of calcium ions 
from subsarcolemmal storage sites as a result of mechanical forces such as sheer stress or 
by other stimulatory compounds via cell surface receptors (Clifford & Hellsten, 2004; 
Furchgott, 1999).  The increase of intracellular calcium leads to the dissociation of the 
inhibitory calveolin-NOS complex by calcium-bound calmodulin, resulting in the 
activation of NOS (Balligand, Feron, & Dessy, 2009; Michel, Feron, Sacks, & Michel, 
1997; Weissman, Jones, Liu, & Gross, 2002).  Independent of calcium-calmodulin, 
activation of iNOS is stimulated by tumor necrosis factor (TNFα), interferon gamma 
(IFNγ) and interleukins, which regulate iNOS expression via Janus kinase and Signal 
Transducer and Activator of Transcription (JAK/STAT) and nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB)  pathways (Z. Yu, Zhang, & Kone, 2002).  
Once in the vascular smooth muscle, NO activates soluble guanylate cyclase, which 
catalyzes the dephosphorylation of guanosine triphosphate (GTP) to cyclical guanosine 
monophosphate (cGMP) that inhibits calcium entry to the cell, activates K+ channels and 
activates myosin light chain phosphatase via protein kinase G (PKG) to cause relaxation 
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of the smooth muscle and local vasodilation (Ahn, Foster, Cable, Pitts, & Sybertz, 1991; 
Ghofrani, Osterloh, & Grimminger, 2006).  Irrespective of the activated NOS isoform, 
synthesized NO diffuses from the cell in which it was produced through the interstitial 
space, in order to promote vasodilation through its effects on vascular smooth muscle.  
 
1.3  Skeletal Muscle Interstitial Space 
In skeletal muscle, the interstitial space represents an important compartment 
located between the vasculature and the tissue.  Water makes up 60% the total body mass 
of an adolescent male, where the intracellular compartment contains two thirds of the total 
body water and the remaining one third is held in the extracellular compartment.  Interstitial 
fluid represents approximately 75% of the extracellular fluid volume.  As such, a 70 kg 
adolescent male contains ~10.5 L of interstitial fluid.  The interstitial fluid provides a 
medium for the diffusion of various metabolic substances and their byproducts between 
the capillary network and the cell.  Additionally, the interstitial compartment has been 
shown to play a functional role in the integration and regulation of various metabolic and 
vasoactive substances (Leuenberger, Johnson, Loomis, Gray, & MacLean, 2008; MacLean, 
Bangsbo, & Saltin, 1999; MacLean, Sinoway, & Leuenberger, 1998; MacLean, Vickery, & 
Sinoway, 2001).   
First described by Delgado et al., (Delgado, DeFeudis, Roth, Ryugo, & Mitruka, 
1972) the microdialysis technique is a unique analytical procedure that allows for the direct 
in vivo investigation of metabolic compounds in the interstitial space.  The microdialysis 
probe is composed of a tubular semipermeable dialysis membrane through which a solution 
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is perfused (termed perfusate) at a constant rate.  Once inserted into the tissue, the dialysis 
membrane is integrated with the interstitial fluid.  Substances that are of greater 
concentration in the interstitial fluid in comparison to the perfusate at the permeable surface 
of the membrane diffuse through the membrane and into the perfusate for collection.  The 
flux of molecules into the perfusate is defined by the diffusional pathlength of molecules 
in the interstitial fluid, which is affected by intrinsic tortuosity and the volume of interstitial 
fluid as it relates to the tissue (MacLean et al., 1999; Nicholson & Phillips, 1981).  This 
has been eloquently described by the modification of Fick’s law of diffusion by MacLean 
et al. (MacLean et al., 1999)  
J = −𝐷𝑝/𝜆
2 · 𝑉𝑂/V · ∇c 
 
where J is the microscopic flux, −𝐷𝑝/𝜆
2 is the diffusion coefficient in perfusate where 
tortuosity is 𝜆,  𝑉𝑂/V is the volume fraction and ∇c is the concentration gradient.  Once 
collected, various analytical techniques can be performed to quantify the molecules under 
investigation.  Therefore, the microdialysis technique allows for the determination of 
vasoactive molecules responsible for the modulation of the local vascular tone as well as 
the transport kinetics of important metabolic substances, such as amino acids, between the 
vascular and intracellular compartments.  
 
 
1.4  Amino Acid Metabolism in Skeletal Muscle 
As the largest organ in the body, the maintenance of healthy skeletal muscle plays 
a critical role in whole body metabolic homeostasis (Clausen, 1986; Juel, 1996; Levy, 
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1999; Sinacore & Gulve, 1993).  Conservation of skeletal muscle mass and integrity is 
dependent on the continuous and dynamic balance between protein synthesis and 
degradation, and central to this process is the availability of amino acids in the free amino 
acid pool (Rennie, Wackerhage, Spangenburg, & Booth, 2004).  In humans, approximately 
130 gms of free amino acids are present in the skeletal muscle intracellular space 
(Wagenmakers, 1998) and, in addition to its role in muscle protein turnover, it participates 
in numerous metabolic reactions that take place throughout the body (Felig, 1973; Wolfe, 
2006).  The branched-chain amino acids (BCAA) valine (Val), leucine (Leu) and isoleucine 
(Iso) are the dominant essential amino acids oxidized in skeletal muscle.  The metabolic 
roles of BCAAs in energy production and protein synthesis regulation in skeletal muscle 
are well established (Brosnan & Brosnan, 2006; Cole, 2015; T.E. Graham, 1995; MacLean, 
Graham, & Saltin, 1994).   
The catabolism of BCAA is a two step enzymatic process, first of which involves 
transamination of the amino acid and the second an oxidative decarboxylation of the 
deaminated product (Harper, Miller, & Block, 1984; Milan, 2011).  The mitochondrial 
branched-chain amino acid aminotransferase (BCAAT) isoenzyme is primarily repsonbile 
for initiating BCAA catabolism (T. R. Hall, Wallin, Reinhart, & Hutson, 1993).  The 
reversible activity of the BCAAT transfers an amino group from BCAA to 2-oxoglutarate 
to form branched-chain ketoacids (BCKA) α-ketoisocaporate (KIC), α-keto-β-
methylvalerate (KMV) and α-ketoisovolerate (KIV) from Leu, Iso and Val, respectively.  
In the subsequent flux-generating step, the BCKA undergo irreversible oxidative 
decarboxilation by the enzymatic activity of branched-chain ketoacid dehydrogenase 
(BCKADH) complex to form isovaleryl-CoA, 3- methylbutyryl-CoA and isobutyryl-CoA 
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from KIC, KMV and KIV, respectively (Cole, 2015; Matthews et al., 1981).  The resulting 
intermediates are further catabolized to produce acetoacetate, acetyl-CoA, proprionyl-CoA 
and succinyl-CoA end products, which enter the TCA cycle for ATP production.  
The potent anabolic effect of BCAA in skeletal muscle has been well established 
(Armsey & Grime, 2002; Blomstrand, Eliasson, Karlsson, & Kohnke, 2006; Chromiak & 
Antonio, 2002; Koopman et al., 2006; Volpi, Kobayashi, Sheffield-Moore, Mittendorfer, 
& Wolfe, 2003).  BCAA-induced stimulation of protein synthesis has been primarily 
attributed to the activation of the mamalian target of rapamycin (mTOR).  A highly 
conserved serine threonine kinase, mTOR is comprised of two distinct mutiprotein 
complexes mTORC1 and mTORC2 (Catania, Binder, & Cota, 2011; M. N. Hall, 2008).  
The mTORC1 complex includes mTOR, Raptor, Deptor, PRAS40 and mLST8/GβL.  
Intramuscular amino acid availability increases levels of Ca2+ which activates mTORC1 
signaling via Ca2+/calmodulin-mediate activation of phosphoinositide 3-kinase (PI3K) 
(Gulati et al., 2008; Nobukuni et al., 2005).  The potent BCAA-mediated stimulation of 
protein synthesis has been primarily attributed to the Leu regulated activation of mTORC1 
by inducing the interaction of Ras-related GTP-binding protein (Rag) with ras-homolog 
enriched in the brain (Rheb) (Kimball & Jefferson, 2006; Norton & Layman, 2006).  
Perturbation of the dynamic balance between protein anabolism and catabolism, where net 
protein breakdown is greater than that of synthesis in skeletal muscle, can result in a 
cachectic, or muscle wasting condition. 
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1.5  Cancer Cachexia 
Cachexia is a serious, life-threatening condition associated with several pathologies 
including cancer (Esper & Harb, 2005; K. C. Fearon, Glass, & Guttridge, 2012; Porporato, 
2016).  Recently, a consensus definition of cancer cachexia has been reached and it is stated 
as follows: 
“Cancer cachexia is defi ned as a multifactorial syndrome characterised by 
an ongoing loss of skeletal muscle mass (with or without loss of fat mass) 
that cannot be fully reversed by conventional nutritional support and leads 
to progressive functional impairment. The pathophysiology is characterised 
by a negative protein and energy balance driven by a variable combination 
of reduced food intake and abnormal metabolism (K. Fearon et al., 2011).” 
Cancer cachexia affects 50-80% of cancer patients and accounts for approximately 20% of 
cancer-related deaths (Argiles, Busquets, Stemmler, & Lopez-Soriano, 2014; Tisdale, 
2002).  Cachectic patients with greater than 15% weight loss exhibit impaired physiological 
function and a drastic reduction in quality of life.  Patient death normally occurs when 
weight loss exceeds 30% (Tisdale, 2002).  Additionally, cachectic patients are less tolerant 
to chemotherapy, radiation therapy and the response to these therapeutic strategies are 
significantly reduced (K. C. Fearon & Baracos, 2010; Vaughan, Martin, & Lewandowski, 
2013).  Attempts at reversing cachexia through nutritional strategies have yielded little 
success indicating that, unlike anorexia, a decrease in caloric intake is not the primary cause 
of the condition (Evans et al., 2008).  Despite being a systemic condition, skeletal muscle 
is the major target of wasting in cachectic patients.  Several proinflammatory cytokines 
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have been associated with the pathogenesis of cachexia, primarily TNFα via the NF-κB 
pathway, IFNγ, interleukin-1 and -6 (IL-1, IL-6) (Acharyya et al., 2004; Baltgalvis et al., 
2008; Han, Weinman, Boldogh, Walker, & Brasier, 1999; Uehara, Sekiya, Takasugi, 
Namiki, & Arimura, 1989).  Within the tissue the lysosomal, calcium-dependent and 
ubiquitin-dependent pathways as well as the proteolysis inducing factor (PIF) have been 
identified as responsible for the intracellular breakdown of protein.  While the lysosomal 
and calcium-dependent pathways contribute to approximately 20% of total protein 
breakdown and PIF is a key component of proteolysis, it is the activation of the ubiquitin 
proteasome pathway (UPP) that plays a major role in muscle wasting (Biolo et al., 2000; 
Lorite, Thompson, Drake, Carling, & Tisdale, 1998; Mitch & Goldberg, 1996; Temparis et 
al., 1994; Williams, Sun, Fischer, & Hasselgren, 1999).  Significant research has been 
performed to elucidate the role of endogenously produced host and tumor-derived factors 
responsible for the progression of cancer related muscle wasting.  However, Wang et al. 
(H. Wang et al., 2015) demonstrated that muscle in tumor bearing mice treated with  
docetaxel (a  chemotherapy agent) underwent atrophy more severely (1.5 fold) than those 
treated with tumor cells alone.  This indicates that chemotherapy significantly contributes 
to the onset of cachexia.  Very little research has focused on delineating host-derived and 
chemotherapy-derived factors, or the possible synergy between the two, in the onset and 
progression of the cachectic condition in cancer patients.  Further research into these 
mechanisms would greatly improve our understanding of the pathophysiology and would 
also provide important insights into possible targets for strategies directed at minimizing 
muscle wasting. 
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1.6  Doxorubicin Chemotherapy 
Since its discovery in 1969 (Arcamone et al., 1969), Doxorubicin (DOX) remains 
one of the most widely used chemotherapeutic agents for the treatment of solid tumors and 
hematological malignancies (Weiss, 1992).  Doxorubicin is an anthracycline antibiotic with 
antineoplastic properties first isolated from cultures of Streptomyces peucetius var. caesius.  
The highly lipophilic nature of DOX is due to a naphthacenequinone nucleus which is 
linked to a hydrophilic amino sugar, daunosamine, through a glycosidic bond at ring atom 
7.  Additionally, DOX contains acidic and basic functions in the ring phenolic groups and 
in the sugar group, respectively, and is therefore both an amphoteric and amphiphilic 
molecule thus allowing it to bind to cell membranes and proteins.  Protonation of the amino 
group of the sugar, forming DOX hydrochloride, increases the aqueous solubility of the 
molecule for administration (Mohan & Rapoport, 2010). 
Doxorubicin induced cytotoxicity has been attributed to DNA intercalation, 
topoisomerase II (TOPII) inhibition and formation of radical oxygen species (ROS).  As a 
planar molecule, DOX preferentially intercalates between neighboring DNA base pairs 
forming a covalent bond between DOX and guanine on one strand of DNA and a hydrogen 
bond between DOX and guanine on the opposing strand, significantly effecting DNA 
replication (Chaires, Fox, Herrera, Britt, & Waring, 1987; Chen, Gresh, & Pullman, 1986; 
Coldwell, Cutts, Ognibene, Henderson, & Phillips, 2008; Minotti, Menna, Salvatorelli, 
Cairo, & Gianni, 2004; Momparler, Karon, Siegel, & Avila, 1976; Yang, Teves, Kemp, & 
Henikoff, 2014).  Topoisomerase II is a highly conserved enzyme that regulates DNA 
topology by releasing torsional stress formed during DNA transcription and is the key 
component in the decatenation of replicated DNA during mitosis (Carpenter & Porter, 
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2004; Pommier, Leo, Zhang, & Marchand, 2010).  Inhibition of TOPII constrains DNA and 
increases torsional stress resulting in double-strand DNA breakages and subsequent cell 
death (Gewirtz, 1999).  The presence of a quinone ring in the chemical structure of DOX 
allows for the one-electron reduction of the drug mediated by oxoreductive enzymes 
xanthine oxidase, NADH dehydrogenase and cytochrome P450 reductase.  This reduction 
converts the quinone to a semiquinone free radical which, in the presence of oxygen, 
undergoes redox cycling to form hydroxyl radicals, superoxides and peroxides causing 
lipid peroxidation, DNA damage and cell death (Doroshow, 1983; Gewirtz, 1999; M. A. 
Graham, Newell, Butler, Hoey, & Patterson, 1987; Singal, Li, Kumar, Danelisen, & 
Iliskovic, 2000).  Taken together, the formation of DOX-DNA adducts, TOPII inhibition 
and ROS formation have been identified as the significant mechanisms responsible for 
DOX-related cellular toxicity.   
Despite its potent toxicity, the clinical use of DOX as a cancer chemotherapeutic is 
limited by a well described dose-dependent and cumulative cardiotoxic side effect leading 
to the development of congestive heart failure (Lefrak, Pitha, Rosenheim, & Gottlieb, 
1973; Singal & Iliskovic, 1998).  Doxorubicin-related cardiotoxicity has been shown to be 
mediated by its primary circulating alcohol metabolite, Doxorubicinol (DOXol), catalyzed 
by the enzymatic activity of carbonyl reductase-1 (CBR1) carbonyl reduction of DOX 
(Kassner et al., 2008).  Potent DOXol-dependent inhibition of the sarcoplasmic reticulum 
calcium pump, the sarcolemmal Na+/K+ pump and mitochondrial F0F1 proton pump in 
cardiomyocytes effectively compromises systolic and diastolic cardiac function (Boucek 
et al., 1987; Minotti et al., 1998; Olson et al., 1988).   
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The impetus to identify and elucidate the underlying mechanisms leading to 
cardiotoxicity has focused DOX-related research to cardiomyocytes.  However, off-target 
cytotoxicity is not limited to cardiomyocytes and recent studies have described the effect 
of DOX on skeletal muscle. Hayward et al. have reported that the exposure of skeletal 
muscle to DOX resulted in a significant and progressive decline in muscular function 
(Hayward et al., 2013).  Additionally, a decline in maximal twitch force and rate of force 
generation as well as an increase in muscular fatigue have also been shown following the 
administration of DOX (Gilliam & St Clair, 2011; van Norren et al., 2009).  Furthermore, 
in clinical practice, it has been shown that chemotherapy can alter insulin sensitivity (Chala 
et al., 2006; Feng et al., 2013).  Insulin is considered to be the main anabolic hormone in 
the body and plays a particularly important role in skeletal muscle where it promotes the 
synthesis and inhibits the degradation of protein and glycogen in the tissue.  De Lima Junior 
et al. (de Lima Junior et al., 2016) have reported that treatment with DOX caused 
hyperglycaemia and insulin resistance mimicking conditions that are similar to cachexia.  
It is important to acknowledge that skeletal muscle health, maintenance and function have 
an influence on a cancer patient’s prognosis and quality of life.  Therefore, further 
investigations into the underlying mechanisms which leads to skeletal muscle dysfunction 
is undeniably warranted. 
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2.  Thesis Purpose 
The importance of skeletal muscle health and function in the quality of life and 
positive prognosis of cancer patients is well established.  However, little is known 
regarding the effect of chemotherapeutic treatment on essential metabolic mechanisms 
responsible for the maintenance of skeletal muscle.  In this thesis, the concurrent 
determination of DOX in the plasma, the intramuscular and interstitial space will provide 
novel insights into the accumulation of the drug in these tissues as well as its effect on the 
systemic availability of the drug.  In addition, the concurrent measurement of NO 
concentrations in these compartments will allow be us to determine if the perfusion of the 
tissue plays a role in the uptake and/or retention of the drug in the muscle.  Lastly, the study 
of the free amino acid pool in the muscle following Dox administration will permit us to 
assess the possible contribution this drug has to non-host induced muscle wasting.  
Ultimately, the aims of this thesis are designed to elucidate the effects that Doxorubicin has 
on skeletal muscle following its administration. 
 
2.1  Objectives 
I. Quantify the accumulation of Doxorubicin and its metabolite Doxorubicinol in 
the plasma, interstitial space, and within skeletal muscle of the rats.  This will 
determine to what extent skeletal muscle may act as a reservoir or sink for the 
accumulation of the drug following administration. 
II. Examine the effect of Doxorubicin administration on nitric oxide 
concentrations in skeletal muscle.  As a local mediator of vascular tone, the 
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assessment of changes in nitric oxide concentration may suggest that tissue 
perfusion is disrupted by chemotherapy drugs, which could in turn affect the 
updake and/or retention.   
III. Investigate the amino acid response in skeletal muscle following the 
administration of Doxorubicin.  This will help us determine whether 
Doxorubicin affects amino acid pools in muscle that may contribute to non-host 
induced cachexia.   
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CHAPTER II 
(Study 1) 
Skeletal Muscle an Active Compartment in the Sequestering and Metabolism of 
Doxorubicin Chemotherapy. 
 
3.  Study 1 Objective:  Describe and quantify the accumulation of Doxorubicin and its 
metabolite, Doxorubicinol, in rat skeletal muscle. 
 
4.  Overview of Study 1 
To study the effect of DOX chemotherapy on skeletal muscle, the first objective 
was to determine the uptake and retention of the drug in the tissue.  As an amphiphilic 
molecule, administered DOX effectively diffuses from the vasculature into the interstitial 
space where cellular uptake occurs.  The chemical nature of DOX allows for the passive 
diffusion of DOX through the cytoplasmic membrane and into the intracellular space.  This 
study investigates the accumulation of DOX and its major metabolite, DOXol, in skeletal 
muscle following its administration in the rat.  Additionally, the relationship between the 
muscular, interstitial and vascular compartments as it relates to the diffusional pathway and 
systemic availability of DOX and DOXol is examined.  This study represents the first time 
that the accumulation of DOX and DOXol have been quantified in skeletal muscle up to 8 
days following the administration of the drug.  In addition, it is also the first time that the 
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relationship between the muscular, interstitial and vascular compartments have been 
examined concurrently following DOX administration.   
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5.1  Abstract 
Doxorubicin remains one of the most widely used chemotherapeutic agents 
however its effect on healthy tissue, such as skeletal muscle, remains poorly understood.  
The purpose of the current study was to examine the accumulation of doxorubicin (DOX) 
and its metabolite doxorubicinol (DOXol) in skeletal muscle of the rat up to 8 days after 
the administration of a 1.5 or 4.5 mg kg-1 i.p. dose.  Subsequent to either dose, DOX and 
DOXol were observed in skeletal muscle throughout the length of the experiment.  
Interestingly an efflux of DOX was examined after 96 hours, followed by an apparent re-
uptake of the drug which coincided with a spike and rapid decrease of plasma DOX 
concentrations.  The interstitial space within the muscle did not appear to play a significant 
rate limiting compartment for the uptake or release of DOX or DOXol from the tissue to 
the circulation.  Furthermore, there was no evidence that DOX preferentially accumulated 
in a specific muscle group with either dose.  It appears that the sequestering of drug in 
skeletal muscle plays an acute and important role in the systemic availability and 
metabolism of DOX which may have a greater impact on the clinical outcome than 
previously considered. 
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5.2  Introduction 
Doxorubicin (DOX) is one of the most widely used chemotherapeutic agents for 
the treatment of solid tumors and hematological malignancies.  DOX induced cytotoxicity 
has been attributed to the inhibition of DNA replication and RNA transcription via DNA 
intercalation, inhibition of topoisomerase II (TOP2A) resulting in TOP2-mediated DNA 
damage, the formation of reactive oxygen species and hydrogen peroxide (Minotti et al., 
2004; Momparler et al., 1976; S. Wang et al., 2004).  Although effective, DOX is strongly 
limited by a dose-dependent and cumulative cardiotoxic side effect which has been 
primarily attributed to its metabolite Doxorubicinol (DOXol) (Minotti et al., 1998; Olson 
et al., 1988).  DOXol is ten times more cytotoxic than DOX and highly cardiotoxic as a 
result of its potent inhibition of the sarcoplasmic reticulum calcium pump, the sarcolemmal 
Na+/K+ pump and the mitochondrial F0F1 proton pump (Boucek et al., 1987; Olson et al., 
1988) 
To date, much of the research remains focused on reducing the cardiotoxic effect 
related to the use of DOX.  However, recent studies have reported that the exposure of 
skeletal muscle to DOX causes significant physiological effects including a progressive 
decline in muscular function (Hayward et al., 2013), a decline in maximal twitch force and 
rate of force generation (Gilliam & St Clair, 2011) as well as increased muscular fatigue 
(van Norren et al., 2009).  Cellular dysfunction has been shown to be related to a significant 
increase in mitochondrial reactive oxygen species (Smuder, Kavazis, Min, & Powers, 
2011b).  In addition, upregulated autophagy and apoptotic pathways are believed to be 
primarily responsible for the DOX-induced decrease in muscle mass (Gilliam & St Clair, 
2011; Smuder, Kavazis, Min, & Powers, 2011a; A. P. Yu et al., 2014).  Despite the growing 
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evidence suggesting a DOX related myotoxicity, the effect of DOX on skeletal muscle 
metabolism and function has received little attention.  
In skeletal muscle, the interstitial space represents an important compartment 
located between the vasculature and the tissue.  It has been shown to play a functional role 
in the regulation and integration of various metabolic substances (Leuenberger et al., 2008; 
MacLean et al., 1999; MacLean, Sinoway, et al., 1998).  Microdialysis is used to directly 
measure these substances in the interstitial space in vivo.  The microdialysis technique, first 
described by Delgado et al. (Delgado et al., 1972), is based on the principle of simple 
diffusion through a semipermeable membrane which allows for the direct measurement of 
compounds, including DOX and DOXol, located within the interstitial space directly at the 
tissue level.  To date, not only has DOX and DOXol not been thoroughly examined in the 
vascular, interstitial and muscular compartments, but the relationship between these 
compartments has never been investigated.  Therefore, the purpose of the current study was 
to investigate the accumulation of DOX and DOXol in skeletal muscle and examine the 
relationship between the muscular, interstitial and vascular compartments following 
administration of DOX in the rat.  Overall, our results clearly indicate that DOX and 
DOXol is sequestered in the skeletal muscle and that there were no differences in the 
sequestering of the drug or its metabolite in muscle groups containing predominantly fast 
or slow muscle fibers.  Therefore, it appears that skeletal muscle plays an acute and 
important role in the systemic availability and metabolism of DOX. 
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5.3  Results 
Plasma DOX. The administration of 1.5 mg kg-1 DOX elevated (P<0.05) arterial 
concentrations of DOX throughout the experiment, with the highest concentration 
observed after 96 (41.4±17.9 nM) and 192 hours (20.3±7.5 nM) post injection as compared 
to baseline.  Similarly, circulating concentrations were elevated (P<0.05) throughout the 
experiment following the administration of 4.5 mg kg-1 DOX.  When compared to the 1.5 
mg kg-1 dose, the concentration of DOX was greater (P<0.05) following the 4.5 mg kg-1 
dose after 24 (300±77 %), 72 (609±119 %), 120 (288±0 %) and 144 (845±147 %) hours 
(Fig 1A)  
Plasma DOXol.  Following the administration of 1.5 mg/kg, DOXol was 
measurable (P<0.05) after 24 hours (1.24±0.25 nM) and remained measurable throughout 
the experiment.  In comparison to the initial concentration observed after 24 hours, the 
levels were decreased (P<0.05) by 51±10 %, 49±11 % and 48±12 % after 72, 120 and 144 
hours respectively.  The 4.5 mg kg-1 dose resulted in an initial DOXol increase (P<0.05) 
after 24 hours (1.26±0.17 nM) which remained stable for the remainder of the experiment.  
Despite the fluctuation difference of DOXol in both doses, the 4.5 mg kg-1 dose was 
observed to be elevated (P<0.05) after 48 (213±7 %) and 72 (157±6 %) hours as compared 
to the 1.5 mg kg-1 dose (Fig 1B).   
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Fig 1.  Doxorubicin (A) and Doxorubicinol (B) concentrations in the arterial plasma 
following the IP administration of 1.5 or 4.5 mg kg-1 Doxorubicin.  (A) Significance 
compared to baseline for the 1.5 mg kg-1 dose is denoted by ✝ and 4.5 mg kg-1 by *.  α 
Denotes an increase (P<0.05) compared to 24, 48, 72, 120, 144 and 168 hours as a result 
of the 1.5 mg kg-1 dose. β Denotes difference (P<0.05) between administered doses.  (B) 
Significance compared to baseline for the 1.5 mg kg-1 dose is denoted by ✝ and 4.5 mg 
kg-1 by *.  α Denotes a decrease (P<0.05) compared to 24 hours.  β Denotes difference 
(P<0.05) between administered doses. 
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Skeletal Muscle DOX. Following the 1.5 mg kg-1 dose, DOX was detectable in the 
WG at each time point (P<0.05) with the exception of 96 and 168 hours.  Additionally, 
these concentrations were elevated (P<0.05) after 48 (0.78±0.24 μmol/kg), 72 (0.32±0.1 
μmol/kg) and 120 (1.23±0.56 μmol/kg) hours post-injection (Fig 2A).  The administration 
of 4.5 mg kg-1 dose resulted in measurable (P<0.05) DOX concentrations at each time 
point.   When compared to 48 hours (1.62±0.61 μmol/kg), 10 and 20-fold decreases 
(P<0.05) were observed after 24 and 96 hours, respectively (Fig 2B).   
With the exception of the 96 hour time point, the concentration of DOX was 
measurable (P<0.05) RG at each time point of the experiment following the administration 
of 1.5 mg kg-1 dose with an initial tissue concentration of 0.90±0.43 μmol/kg after 24 hours 
(Fig 2A).  DOX was measurable (P<0.05) at the 48, 72, 120, 144, 168 and 192 hour time 
points following the administration of the 4.5 mg kg-1 dose.  The concentration of DOX 
significantly decreased 200-fold after 168 hours and 26-fold after 192 hours when 
compared to the 72 hour (4.13±2.16 μmol/kg) time point (Fig 2B).   
Subsequent to the 1.5 mg kg-1 dose, DOX concentrations in the PL were 
measurable at each time point and were elevated (P<0.05) to 1.38±0.44 μmol/kg after 48 
hours.  Concentrations subsequently decreased (P<0.05) after 120 (726±0 %), 144 (690±6 
%), 168 (575±0.2 %) and 192 hour (675±1 %) in comparison to the 48 hour time-point (Fig 
2A).  The administration of 4.5 mg kg-1 resulted in measurable concentrations of DOX 
after 72 hours (0.14±0.06 μmol/kg, P<0.05) which remained consistent for the remainder 
of the experiment (Fig 2B).  
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Fig 2.  Doxorubicin concentrations in skeletal muscle groups following the IP 
administration of (A) 1.5 mg kg-1 or (B) 4.5 mg kg-1 of Doxorubicin.  (A) * Denotes 
significance when compared to baseline for all muscle groups.  α Indicates the highest 
points of accumulation of DOX (P<0.05) in the white gastrocnemius, β Indicates the 
highest point of accumulation (P<0.05) in the plantaris and ε Indicates the point of 
greatest accumulation of DOX (P<0.05) in the soleus.  (B) * Denotes significance when 
compared to baseline for all muscle groups.  α Denotes a decrease (P<0.05) compared to 
48 hours in the white gastrocnemius and δ denotes a significant decrease compared to 72 
hours in the red gastrocnemius.  There are no significant differences between muscle 
types at any time point in either administered doses. 
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The administration of 1.5 mg kg-1 DOX resulted in measurable concentrations of 
DOX within the SOL at each time point with the highest (P<0.05) concentration (1.23±0.39 
μmol/kg) occurring after 48 hours (Fig 2A).  DOX was measurable (P<0.05) in the SOL at 
each time point with the exception of the 24, 72 and 96 hour time points following the 4.5 
mg kg-1 dose (Fig 2B).   
Interestingly, no consistent differences between intracellular DOX concentrations 
were observed throughout the course of the experiment when comparing muscle groups at 
either the administration of 1.5 or 4.5 mg kg-1 dose.  Furthermore, there were no significant 
dose-dependent differences in DOX concentrations at any time point when comparing 
administered doses.   
Skeletal Muscle DOXol. DOXol was measurable (P<0.05) in the WG after 72, 144 
and 192 hours as a result of the administered 1.5 mg kg-1 dose (Fig 3A).  The 
administration of 4.5 mg kg-1 dose resulted in measureable (P<0.05) DOXol 
concentrations after 48, 72, 120, 144 and 192 hours (Fig 3B).   
The administration of 1.5 mg kg-1 dose resulted in measurable DOXol 
concentrations (P<0.05) in the RG after 48, 72, 120, 144 and 192 hours (Fig 3A).  The 4.5 
mg kg-1 dose resulted in measurable (P<0.05) tissue concentrations of DOXol at 48, 72, 
144, 168 and 192 hours (Fig 3B).   
The 1.5 mg kg-1 dose resulted in measurable (P<0.05) concentrations of DOXol in 
the PL after 24, 48, 72, 120 and 192 hours (Fig 3A), whereas the 4.5 mg kg-1 dose resulted 
in measurable (P<0.05) levels of DOXol after 24, 120, 144, 168 and 192 hour (Fig 3B).   
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Fig 3.  Doxorubicinol concentrations in skeletal muscle groups following the IP 
administration of (A) 1.5 mg kg-1 or (B) 4.5 mg kg-1 of Doxorubicin.  * Denotes 
significance when compared to baseline for all muscle groups.  There are no significant 
differences between muscle types at any time point in either administered doses. 
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DOXol was measurable (P<0.05) in the SOL after 48, 72, 120, 144 and 192 hours 
following the 1.5 mg kg-1 dose (Fig 3A). Similarly, DOXol was measurable (P<0.05) after 
48, 72, 96, 120 and 144 hours post-injection of the 4.5 mg kg-1 dose (Fig 3B).   
Interestingly, there were no consistent differences between DOXol concentrations 
when comparing muscle groups following the 1.5 mg kg-1 or 4.5 mg kg-1 dose. 
Additionally, there were no significant dose-dependent differences in DOXol 
concentrations at any time point when comparing administered doses.   
Interstitial DOX. Following the 1.5 mg kg-1 dose, interstitial DOX concentrations 
were measurable (P<0.05) after 48 hours (0.58±0.28 nM) then decreased until 120 hours 
(0.24±0.1 nM; P<0.05) where levels remained stable for the remainder of the experiment.  
Similarly, as a result of the 4.5 mg/kg, DOX was measurable (P<0.05) after 48 hours 
(0.4±0.18 nM) and decreased until 96 hours (0.44±0.18 nM; P<0.05) where concentrations 
remained stable for the remainder of the experiment.  There were no significant differences 
in interstitial DOX concentrations at any time point when comparing between administered 
doses (Fig 4A).  
Interstitial DOXol. Interstitial DOXol concentrations were measurable (P<0.05) 
after 48, 144 and 192 hours post-administration of the 1.5mg kg-1 dose.  Subsequent to the 
4.5 mg kg-1 dose, DOXol was measurable after 48 hours (0.16±0.07 nM) and remained 
stable for the remainder of the experiment.  There were no significant differences between 
interstitial DOXol concentrations between doses (Fig 4B).   
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Fig 4.  Doxorubicin (A) and Doxorubicinol (B) concentrations in the interstitial space of 
skeletal muscle following the IP administration of 1.5 or 4.5 mg kg-1 Doxorubicin.  ✝ 
Designates significance compared to baseline for the 1.5 mg kg-1 dose.  * Designates 
significance compared to baseline for the 4.5 mg kg-1 dose. 
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5.4  Discussion 
The focus of the current study was to investigate the accumulation of DOX and 
DOXol in skeletal muscle and examine the relationship between the muscular, interstitial 
and vascular compartments following the administration of DOX in the rat.  A major 
finding in this study was the apparent role that skeletal muscle plays in the sequestering of 
DOX following its administration.  This was made evident as plasma DOX levels were 
inversely proportional to skeletal muscle concentrations (data presented Figs 1 and 2).  A 
static pool of DOX was established in the interstitial space which maintained in dynamic 
equilibrium between the vasculature and skeletal muscle which did not change over time 
or with an increase in dose.  As such, the interstitial space does not appear to represent a 
rate limiting factor in the diffusion kinetics of the drug.  Furthermore, the relationship 
between the three compartments was impartial to muscle groups predominantly composed 
of different fiber types.   Hence, it appears that skeletal muscle plays an acute and important 
role in the systemic distribution of DOX and may have a greater impact on drug availability 
than previously considered. 
DOX was administered IP in order to simulate previous studies that have examined 
the cardiotoxic effects of DOX in the rat (Guerra et al., 2005; Jensen, Acton, & Peters, 
1984; Teraoka, Hirano, Yamaguchi, & Yamashina, 2000; Yen, Oberley, Vichitbandha, Ho, 
& St Clair, 1996).  A single low dose of DOX was used in order to minimize the drug-
induced risk of cardiotoxicity.  For example, previous studies have utilized a variety of 
concentrations and treatment regimens documenting significant cardiomyocyte damage.  
Iqbal et al. (Iqbal, Dubey, Anwer, Ashish, & Pillai, 2008) administered a single 20 mg kg-
1 dose IP and observed the induction of acute cardiotoxicity after 48 hours and up to 7 days 
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post administration.  A study by Nagi et al. (Nagi & Mansour, 2000) reported that a single 
dose of 15 mg kg-1 IP induced cardiotoxicity after 24 and 48 hours and Jensen et al. (Jensen 
et al., 1984) noted that a 10 mg kg-1 or less total dosage did not cause cardiac failure.  
Although Arola et al. (Arola et al., 2000) reported minor cardiomyocyte apoptosis after 3 
days following the injection of 1.5 mg kg-1 and 5 mg/kg, it remains unclear whether this 
significantly altered cardiac performance.  Cumulative doses have been studied where 1 
mg kg-1 (IP) was administered 15 times over 3 weeks resulted in cardiac dysfunction 
(Teraoka et al., 2000) and 1.5 mg kg-1 weekly for 9 weeks resulted in severe 
cardiomyopathy (Guerra et al., 2005).  What these studies have in common is the focus on 
the long term effects of DOX where, to our knowledge, little or no attention has been given 
to the early stages of DOX accumulation in skeletal muscle.  As such the current study 
investigated DOX concentrations 24 hours sequentially up to 192 hours.  With the 
aforementioned factors taken into consideration, the concentrations used in this study 
provided a dose-related experimental contrast while minimizing the drug-induced risk of 
cardiac dysfunction associated with the higher doses.  Additionally, the time frame allows 
for the examination of acute DOX accumulation in skeletal muscle as well as the dynamic 
between the circulation and the interstitial space within the skeletal muscle.   
This study represents the first time that sequential measurements of plasma DOX 
concentrations have been made for 8 days (192 hours) after IP administration.  Despite the 
threefold increase in administered dose from 1.5 mg kg-1 to 4.5 mg/kg, a stable circulating 
concentration of DOX was maintained throughout the 8 days with the exception of a spike 
in concentration after 4 days (96 hours).  This stable concentration may be attributed to the 
enzymatic breakdown of DOX once in the circulation.  It is well known that DOX is 
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enzymatically reduced to a number of metabolites (Thorn et al., 2011).  The reduction of 
DOX to its major metabolite, DOXol (Mordente, Meucci, Silvestrini, Martorana, & 
Giardina, 2009) by way of carbonyl reductase-1 (Kassner et al., 2008), carbonyl reductase-
3 (Bains et al., 2010) or aldo-keto reductases (Heibein, Guo, Sprowl, Maclean, & 
Parissenti, 2012) is of particular clinical importance as it is 10 times more cytotoxic than 
DOX (Mahnik, Rizovski, Fuerhacker, & Mader, 2006) and has been identified to be 
responsible for the cardiotoxic effect related to DOX therapy (Olson et al., 1988).  DOXol 
concentrations in the plasma did not have the same degree of variability within the dose 
groups or degree of dose response as that observed in the DOX concentrations.  What is 
interesting, however, is that despite the increase in DOXol concentrations between doses 
after 48 and 72 hours, concentrations remained constant for the remainder of the 
experiment indicating that the breakdown of DOX to DOXol does not complement the 
increase in administered dose.  This would indicate that a threshold in the enzymatic 
breakdown of DOX to DOXol may exist and a maximal rate was achieved 24 hours after 
drug administration which resulted in a constant circulating concentration of the cytotoxic 
metabolite.  The persistent circulation of DOX represents a significant clinical importance 
as the repeated administration of DOX may further increase circulating concentrations of 
the drug and its toxic metabolite above that established by the initial dose.  While this may 
be beneficial in assuring the delivery to the tumor, increasing the drug and, as a result, its 
toxic metabolite may have a greater impact on healthy tissue.  
The current study proposes that the persistent circulating concentration of DOX is 
attributed to the acute sequestering of the drug in the skeletal muscle which is primarily 
responsible for the timely release of the drug back into the circulation.  Previous studies 
 32 
have focused on the accumulation of DOX in the heart, liver, spleen, lung, brain and kidney 
(Arnold, Slack, & Straubinger, 2004; Ciaccio et al., 1993; Sacco et al., 2003; Shin, 
Matsunaga, & Fujiwara, 2010; van Asperen, van Tellingen, Tijssen, Schinkel, & Beijnen, 
1999).  However very few have investigated the accumulation in skeletal muscle 
(Doroshow, Tallent, & Schechter, 1985; Gibson, Quinn, Pfannenstiel, Hydock, & Hayward, 
2013; Hayward et al., 2013).  The accumulation of DOX was observed in the muscle at 
each time point regardless of the administered dose.  What was most surprising was the 
consistent efflux of DOX at 96 hours which was quickly followed by a re-accumulation 
after 120 hours with both doses.  The rapid elimination of DOX from the skeletal muscle 
coincides with the notable increases seen in plasma as previously discussed.  To our 
knowledge no mechanisms to date have been identified that may explain these results, 
although these data may indicate an active survival mechanism by the skeletal muscle in 
order to export DOX from the cytosol once a toxic concentration has been attained.  As 
previously mentioned, a constant rate of DOX breakdown from the circulation may have 
been established after 24 hours of drug administration.  As such, the sequestering of DOX 
in skeletal muscle may occur to assist in minimizing the toxic circulating concentrations 
while being subjected to the rate limiting enzymatic breakdown by the liver.  It is also 
possible that after approximately 72 hours the sequestration of DOX into the skeletal 
muscle by way of passive diffusion (Skovsgaard & Nissen, 1982), a threshold limit may 
have been achieved.  The subsequent transcription of transport proteins such as RALBP1 
(Awasthi et al., 2008) and/or P-glycoprotein (Georges, Bradley, Gariepy, & Ling, 1990) 
required for the active export of DOX may be initiated resulting in the efflux of DOX back 
into the circulation.  The opportunistic release of drug back into the circulation and 
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subsequent breakdown reduces toxicity both at tissue and systemic level.  The apparent re-
uptake of DOX into the skeletal muscle tissue may be a function of the rapid reintroduction 
of DOX into the circulation and resulting diffusion back into the tissue.  DOXol was 
measurable in skeletal muscle up to 8 days, regardless of the administered dose.  Although 
quantifiable, the accumulation of DOXol was minimal up to 96 hours which corresponds 
to the aforementioned metabolic breakdown of DOX.  To our knowledge, data regarding 
the accumulation of DOXol in skeletal muscle remains limited (B. J. Cusack, Young, 
Driskell, & Olson, 1993; Mushlin et al., 1993; Peters, Gordon, Kashiwase, & Acton, 1981)  
and the mechanisms involved in the apparent accumulation of DOXol in the skeletal 
muscle remains poorly understood.  It may be possible that DOXol enters the cell by 
passive diffusion, in a similar process as that of DOX.  In support of this notion, the 
constant circulating concentration of DOXol that was established after 96 hours would 
explain the increased accumulation in skeletal muscle.  It is also possible that the 
accumulated concentration of DOX in skeletal muscle is broken down to DOXol at a steady 
rate by the presence of carbonyl reductase-1 resulting in a constant rate within the tissue 
(Kassner et al., 2008; Lim et al., 2013).  Given the well-established cytotoxic nature of 
DOXol, more research is necessary to understand the role that skeletal muscle plays in the 
accumulation and metabolism of this metabolite.  It should be noted that the route of 
administration as well as the inherent individual differences of drug uptake from the gut 
may have contributed to these results. Alternative routes such as IV may yield a distinct 
contrast in concentrations between doses.  Furthermore, as a limitation of the experimental 
procedures, these data are not paired as the same measurements were not made from the 
same rat over the course of the experiment (192 hours).  Skeletal muscle represents 
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approximately 40% of the body mass and constitutes an important compartment which 
appears to play a major role in the sequestering of DOX.  The resulting accumulation of 
the drug in the muscle may have a more immediate impact on the tissue than previously 
believed.  More concerningly, the apparent sequestering may significantly limit the amount 
of drug intended for the target tissue (i.e. tumor) upon repeated administration while 
inadvertently increasing concentrations while unnecessarily elevating DOXol in the 
healthy tissue. 
The interstitial space within the skeletal muscle did not appear to represent a 
significant rate limiting compartment for the uptake or release of DOX or DOXol from the 
tissue to the circulation irrespective of the dose.  Interstitial DOX and DOXol 
concentrations were stable throughout the experiment as well as comparable between the 
two doses.  This suggests that the rate of appearance of DOX and DOXol in the interstitial 
space from the vasculature appears to be matched by the rate of disappearance of the drug 
and its metabolite from the interstitial space into the muscle.  A dynamic equilibrium 
appears to form resulting in no net accumulation in the interstitial space.  This is further 
supported by the finding that the reciprocal efflux of DOX and DOXol from the muscle 
back into the plasma at 96 hours did not result in any significant accumulation of these 
compounds in the interstitial space, suggesting that the dynamic equilibrium is sustained 
in both directions.  Additionally, these data demonstrate that the microdialysis technique is 
an effective tool for the in vivo analysis of drug concentrations within the extracellular fluid 
of skeletal muscle, and as such, may be an important tool in the assessment of drug delivery 
kinetics.   
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Muscle groups which differ in fiber type distribution were examined to further 
investigate the factors involved in the accumulation of DOX and DOXol within skeletal 
muscle.  The SOL predominantly consists of ~97 % of Type I fibers whereas the WG is 
~88 % Type IIB fibers (Bloemberg & Quadrilatero, 2012).  The RG (~39 % Type I, ~30 % 
Type IIA) and PL (~45 % Type IIX, ~21 % Type IIA) are considered as a mixed based on 
the distribution of fiber types (Bloemberg & Quadrilatero, 2012).  Interestingly, there was 
no evidence that DOX preferentially accumulated in a specific muscle group at either the 
1.5 mg kg-1 or 4.5 mg kg-1 dose.  Additionally, no differences in DOX concentrations were 
observed when comparing levels between the two doses.  It has previously been shown that 
once in the cytosol DOX has a high affinity for cardiolipin (Goormaghtigh, Huart, Praet, 
Brasseur, & Ruysschaert, 1990), an important phospholipid expressed in the mitochondrial 
membrane.  It would be expected that a preferential accumulation of DOX would occur in 
the oxidative Type I muscle as it relies heavily on mitochondrial activity as compared to 
the Type II glycolytic muscle.  Though, the current data supports the contention proposed 
by Anderson et al. (Anderson, Xiong, & Arriaga, 2004) who has reported a high degree of 
variability of the accumulation of DOX in the mitochondria.  It is well known that the 
capillary network within the skeletal muscle differs greatly between fiber types where the 
capillary to fiber ratio is significantly higher in Type I muscle compared to that of Type II 
(Erzen, Janacek, & Kubinova, 2011; Murakami et al., 2010).  In the current study, it does 
not appear that the difference in perfusion of the tissue plays a role in the accumulation of 
DOX in the skeletal muscle.  The data in the current study represent basal muscle 
conditions as there was minimal muscle exertion over the course of the experiment.  Muscle 
stimulation or exercise may expose fiber type differences in the accumulation of DOX and, 
 36 
as such, further study is required to better explore this possibility.  There was some 
individual variation in DOXol accumulation amongst the muscle groups but overall there 
was no difference between muscle groups regardless of the administered dose.  As 
previously noted, the mechanisms responsible for the influx and efflux of DOXol from 
skeletal muscle has not yet been elucidated and even less is known about the commonalities 
shared between fiber types leading to the results seen in this study.  Considering the 
resemblance of data between DOXol and DOX, it is within reason to believe that muscle 
fiber types do not affect DOXol accumulation in basal conditions.  Further study is required 
to explore the possible role that increased muscle use may have on accumulation. 
Overall, this study clearly shows that skeletal muscle plays an important role in the 
metabolism of DOX and may significantly alter its therapeutic impact.  The rapid and 
sustained accumulation of the drug in the muscle as a result of a single injection may initiate 
factors leading to the characteristic dysfunction previously described.  Furthermore, the 
apparent sequestering of the drug in the muscle effectively reduces systemic concentrations 
and favors metabolic breakdown.  In turn, this decreases the drug intended for the tumor 
severely reducing the therapeutic impact prompting repeated doses typical of 
chemotherapy regimens.  This represents a therapeutic and clinical paradox: The repeated 
administration of the drug increases the exposure of the tumor to the chemotherapy, while 
the inherent accumulation of the drug in skeletal muscle exacerbates the initial detrimental 
effects, ultimately reducing the clinical outcome.  The possible manifestation of skeletal 
muscle toxicity before that of a cumulative and dose-dependent cardiotoxicity may have 
serious implications in the clinical assessment and modulation of Doxorubicin 
chemotherapy.  
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5.5  Materials and Methods  
5.5.1  Animals 
All of the experimental procedures in the study were approved by the Laurentian 
University Animal Care Committee.  Male Sprague-Dawley rats (n=102, 434±8 g) were 
obtained from Charles River Laboratories (Senneville, QC) and were housed according to 
Standard Operating Procedures and Policies for the Housing and Environmental 
Enrichment of Rodents at the Laurentian University Animal Care Facility.  Experiments 
began after a one week acclimation period. 
5.5.2  Pre-experimental procedures  
Experimental groups.  Rats were injected with Doxorubicin (Doxorubicin 
Hydrochloride. Pfizer, Canada) at a dose of 1.5 mg kg-1 (Group 1 to 8) or 4.5 mg kg-1 
(Group 9 to 16), administered intraperitoneally (IP).  A sham injection of saline solution 
was administered to a control group (IP, n=6).  Once administered, rats were randomly 
grouped into experimental endpoints (n=6) of 24, 48, 72, 96, 120, 144, 168 or 192 hours 
post-injection (Fig 5A).  This dose was selected in order to examine the acute effects of the 
drug on skeletal muscle while minimizing the potential for cardiotoxicity.  
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Fig 5.  Organization of experimental groups and experimental procedures.  (A) Schematic 
representation of the experimental groups receiving an injection of 1.5 mg kg-1 dose 
(groups 1-8) or 4.5 mg kg-1 (groups 9-16) of DOX IP.  A sham injection is administered 
to the control group (Ctrl). (B) Representation of the experimental proceedings for 
dialysate, blood and tissue collection following microdialysis probe insertion and carotid 
artery cannulation.  
 
Microdialysis probes. A complete description of the construction of the 
microdialysis probes has previously been outlined (Hellsten, Maclean, Radegran, Saltin, & 
Bangsbo, 1998). Briefly, microdialysis fibers were constructed using Spectra Microdialysis 
fibers (Spectrum, VWR International) with a molecular weight cut-off of 13 kDa and 
Polyamide-100II tubing (MicroLumen, Tampa FL) cut to 9.5 and 5 cm lengths.  The ends 
of the fiber were inserted 1 cm into the hollow polyamide tube and glued.  The exposed 
portion of the fiber (diffusible) between the polyamide tubes measured 1.0 cm in length. 
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5.5.3  Experimental procedures  
Animals. On the day of the experiment, the rats were placed into an induction 
chamber and anaesthetized using an EZ-150 vaporizer unit (EZ-Anesthesia, Euthanex 
Corporation, Palmer, PA), which blends oxygen (100% O2 Praxair, Sudbury, ON) and 
isoflurane (5 %).  Once anaesthetized, the rats were removed from the chamber and placed 
onto a heated pad while its nose was placed in to a nosepiece supplying a continuous 
delivery of oxygen and isoflurane (2-2.5 %).  The animals remained under anaesthesia 
throughout the experiment and the plane of anaesthesia was routinely checked by toe 
pinches.  Heart rate and oxygen saturation were monitored throughout the experiment using 
a pulse oximeter (SurgiVet) attached to the base of the tail.  Body temperature (between 
36–37oC) was maintained using a heated surgical bed (EZ-Anaesthesia) and a heating 
lamp.  Following the completion of the experiment the animals were euthanized by 
decapitation.     
Probe insertion.  Using curved dissecting scissors, incisions were made at the base 
of the leg and the skin was manually pulled back until the entire leg was exposed (Fig 6A) 
and then the excess skin was removed.  A 21 gauge curved cannula was inserted anteriorly 
into the muscle along the muscle’s natural fibre orientation (Fig 6B) and acted as a guide 
for the microdialysis probe.  Once the cannula was in place, the 9.5 cm portion of the probe 
is inserted caudally through the cannula and extended past the foot (Fig 6C).  As soon as 
the diffusible portion of the probe was oriented into the muscle, then the 5 cm portion of 
the probe was held in place while the cannula was retracted out of the tissue leaving the 
probe in place (Fig 6D). 
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Fig 6.  Experimental procedure for microdialysis probe insertion.  (A) Exposing the 
medial and lateral gastrocnemius muscle.  (B) Insertion of 21 gauge cannula.  (C) 
Microdialysis probe insertion guided by the cannula.  (D)  Location of the diffusible 
membrane within the muscle. 
 
Experimental protocol. Two microdialysis probes were inserted into the hind limb, 
one in the lateral gastrocnemius and one in the medial gastrocnemius muscle of the same 
limb (n=2 probes per animal) as the opposite limb was used for muscle extraction.  
Following probe insertion, the fibers were perfused (model 102, CMA) at a rate of 3 
µL/min with Ringer’s solution.  It is recognized that probe insertion results in some cellular 
disruption therefore traditionally a 60 min. equilibration period prior to the initiation of the 
experiment was used to ensure that the external environment surrounding the probes had 
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stabilized and all cellular damage had dissipated (MacLean et al., 2001). Subsequently, the 
skin and tissue covering the left carotid artery was removed.  A 20 gauge cannula was 
inserted into the exposed artery and sutured in place.  Heparinized saline (100 μL) was 
injected into the artery to maintain patency in preparation for blood sampling. 
Following the equilibration period the experimental protocol was initiated (Fig 5B) 
where dialysate was collected for a period of 75 minutes in order to obtain sufficient 
volume that was required for analysis.  Dialysate samples were collected in microcentrifuge 
tubes and immediately sealed to prevent evaporation and stored at -80oC until analysis.  
Arterial blood samples were collected during the collection of dialysate at 0, 35 and 75 
minutes.  Samples were spun at 15,000 rpm for 25 seconds, plasma was separated and 
stored at -80oC until analysis.  Upon completion of dialysate and blood collection the 
plantaris (PL), soleus (SOL), medial gastrocnemius (WG) and lateral gastrocnemius (RG) 
muscles of the opposite leg used for microdialysis were extracted and inserted into 
cryogenic vials then flash frozen in liquid nitrogen and stored at -80oC until analysis. 
5.5.4  Sample analysis 
HPLC. Quantification of DOX and DOXol were determined by HPLC analysis 
(Waters e2695, 2475 Fluorescence Detector, Waters Corporation) with an ACE CN column 
(Advanced Chromatography Technologies, UK).  The mobile phase was composed of a 
10mM sodium phosphate monobasic (pH 4.0) solution as well as a 100 % acetonitrile 
solution and a volume of 90 μL was used for analysis.  Detection was made by fluorescence 
(2475 Fluorescence Detector, Waters Corporation) at 480 nm excitation and 560 nm 
emission. 
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Interstitial DOX, DOXol.  Quantification of interstitial DOX and DOXol 
concentrations where determined by HPLC analysis.  The collected dialysate samples 
represent an ultra-clean filtrate and did not require any pre-analysis preparation.  Dialysate 
and perfusate blanks as well as dialysate samples from control animals were used to 
confirm the quality and purity of the samples analyzed.  Compounds were quantified by 
comparison with a standard curve (Doxorubicin Hydrochloride. Pfizer, CA; Doxorubicinol 
Citrate. TRC, CA). 
Skeletal Muscle DOX, DOXol.  Muscle samples were homogenized using a 67 μM 
potassium phosphate solution containing a 0.625 μM Daunorubicin (Daunorubicin 
hydrochloride, Sigma) internal standard, to a concentration of 125 mg muscle/mL of 
solution.  Subsequently, 200 μL of 50:50 (v/v) 40% ZnSO4 and 100% methanol was added 
to 150 μL homogenate and vortexed for 2 minutes.  Samples were then placed in the 
centrifuge at 13,000 rpm for 10 minutes and supernatant was used for HPLC analysis.  
Compounds were quantified by comparison with a standard curve and corrected by internal 
standard. 
Plasma DOX, DOXol.  For this analysis, a 133 μL of 50:50 (v/v) 40 % ZnSO4 and 
100 % methanol containing 0.0625 μM Daunorubicin internal standard was added to 100 
μL of plasma and vortexed for 2 minutes.  Samples were then placed in the centrifuge at 
13,000 rpm for 10 minutes and supernatant was used for HPLC analysis.  Compounds were 
quantified by comparison with a standard curve and corrected by internal standard. 
Probe recovery.  Probe recovery was determined using an in vitro method 
previously described by Li et al. (Li, King, & Sinoway, 2003)  Probes were immersed in a 
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Petri dish filled with a predetermined concentration of DOX and DOXol and perfused with 
Ringer’s solution.  Probe recovery was determined by dividing the concentration of DOX 
and DOXol in the recovered dialysate by the concentrations in the Petri dish.  A flow rate 
of 3 μL/min was used in this experiment, yielding a 10 and 18 % recovery rate of DOX 
and DOXol, respectively.  It is important to note that, for the scope of this study, the stability 
of the environment surrounding the probe is critical as it allows for the constant collection 
of undisturbed concentrations of the drug and its metabolite.  As such, collections were 
done in resting conditions and after a 60 minute period of equilibration. 
Statistics. Changes in plasma, interstitial and muscle DOX and DOXol 
concentrations in comparison to baseline, which ultimately represents zero drug 
concentration, were analyzed using ANOVA and significance was accepted at P<0.05.  
Similarly, the differences between doses and each time points were analyzed using ANOVA 
where significance was accepted at P<0.05.  When significant changes were observed in 
the comparisons, a Tukey’s post hoc test for multiple comparisons was used to determine 
where the significance occurred.  All values used in graphical representations are displayed 
as mean ± SEM. 
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CHAPTER III 
(Study 2) 
Doxorubicin chemotherapy affects intracellular and interstitial nitric oxide 
concentrations in skeletal muscle. 
 
6.  Study 2 Objective: Examine the effect of Doxorubicin administration on nitric oxide 
concentrations in skeletal muscle and the interstitial space. 
 
7.  Overview of Study 2 
Perfusion of skeletal muscle is essential in assuring the health and function of the 
tissue.  The stringent regulation of competing local vasoconstrictive and vasodilatory 
molecules is necessary to meet fluctuations in metabolic demand.  As a potent vasodilatory 
molecule, the ubiquitous production of nitric oxide in skeletal muscle plays an important 
role in the proper regulation of local vascular tone.  Nitric oxide diffuses from the cell in 
which it is produced through the interstitial space to the targeted vascular smooth muscle 
to exert its vasodilatory effect.  It is well established that alterations in nitric oxide 
homeostasis leads to significant physiological effects including dysregulation of local 
blood perfusion in the tissue, increased radical oxygen generation and peroxynitrite 
formation.  In the previous chapter, a bolus injection of DOX resulted the sequestering of 
the drug in skeletal muscle up to 8 days following its administration.  Doxorubicin has 
shown to effect nitric oxide synthase expression in cancer cells, cardiomyocytes and 
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skeletal muscle however direct measurements of nitric oxide following the administration 
of DOX has never been investigated.  This study concurrently examines intracellular and 
interstitial concentrations of nitric oxide in skeletal muscle following the administration of 
DOX, highlighting the possible effects of nitric oxide dysregulation on the tissue and the 
potential role of nitric oxide in the timely release of the drug from the tissue. 
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8.1  Abstract 
The role of nitric oxide (NO) in Doxorubicin (DOX; cancer chemotherapeutic) 
induced cardiotoxicity is well established.  In skeletal muscle (SM), NO regulation plays a 
critical role in health, biogenesis and function.  Despite the increasing evidence that 
indicates the negative impact of DOX on SM function, the effect of DOX on NO production 
in SM has yet to be examined.  The purpose of the current study was to simultaneously 
examine intracellular and interstitial NO concentrations in the SM following the 
administration of DOX.  A single dose of 1.5 or 4.5 mg/kg was administered 
intraperitoneally to male Sprague-Dawley rats and interstitial (IS) and intracellular (IC) 
NO was quantified every 24 up to 192 hrs. post injection.  There was no significant 
difference in IC NO following the injection of 1.5 mg/kg DOX when compared to control, 
however the administration of 4.5 mg/kg DOX resulted in lower (P<0.05) concentrations 
of NO in the IC.  Interestingly, a consistently higher (P<0.05) concentration of NO in the 
IS was established following the administration of 1.5 mg/kg compared to control while no 
significant changes in IS NO resulted from the administration of the 4.5 mg/kg dose.  The 
fluctuation of IS and IC NO where not a result of substrate availability as arginine 
concentrations remained stable throughout the experiment.  By utilizing the microdialysis 
technique, we have simultaneously quantified for the first time the IS and IC concentrations 
of NO in SM following DOX administration.  These data provide important insight in the 
possible mechanisms leading to DOX related SM dysfunction. 
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8.2  Introduction 
Nitric oxide (NO) is a key signaling molecule implicated in various physiological 
processes including local blood flow regulation, platelet aggregation and 
neurotransmission (Archer et al., 1994; Calabrese et al., 2007; Riddell & Owen, 1999).  In 
the presence of L-arginine (Arg), NADPH and molecular oxygen, NO is endogenously 
produced by the enzymatic activity of three nitric oxide synthase (NOS): endothelial, 
neuronal and inducible isoforms (eNOS, nNOS and iNOS respectively) (Stamler & 
Meissner, 2001).  In skeletal muscle, significant physiological consequences are attributed 
to fluctuations in NO production, from impairment of skeletal muscle growth and 
differentiation to decreased muscle performance (De Palma et al., 2014; Stamler & 
Meissner, 2001).  It has been recognized that during chemotherapeutic treatment, 
disruption of healthy skeletal muscle is an indicator of poor treatment results, and increased 
patient mortality (Antoun, Baracos, Birdsell, Escudier, & Sawyer, 2010; Prado et al., 2009).  
Doxorubicin (DOX) is a widely used and highly effective cytotoxic agent used in 
the treatment of a broad spectrum of cancers (Carter, 1975; Gewirtz, 1999).  DOX induced 
cytotoxicity has been attributed to the inhibition of DNA replication and RNA transcription 
via; 1) DNA intercalation, 2) inhibition of topoisomerase II (TOP2A) resulting in TOP2-
mediated DNA damage and, 3) the formation of reactive oxygen species and hydrogen 
peroxide (Minotti et al., 2004; Momparler et al., 1976; S. Wang et al., 2004).  The use of 
DOX chemotherapy is constrained by a dose-dependent and cumulative cardiotoxic effect 
which has been primarily attributed to its potent cytotoxic metabolite, Doxorubicinol 
(Minotti et al., 2004; Olson & Mushlin, 1990).  Much of the attention regarding DOX and 
its effect on NO production has been primarily focused on its effect in cardiomyocytes 
 49 
(Aldieri et al., 2002; Octavia et al., 2012; Zhang et al., 2012) where interesting progress 
has been made to reduce cardiotoxicity with dietary nitrates (Xi et al., 2012).  Recent 
studies have reported a decline in muscular function, a decrease in force generation and 
increased muscular fatigue as a result of DOX treatment (Gilliam & St Clair, 2011; 
Hayward et al., 2013; van Norren et al., 2009).  Similar to its well described toxic effect on 
myocardial tissue, significant increases in mitochondrial reactive oxygen species (ROS) as 
well as upregulated autophagy and apoptotic pathways are believed to be primarily 
responsible for DOX-related muscular dysfunction (Gilliam & St Clair, 2011; Smuder et 
al., 2011a; A. P. Yu et al., 2014).  Little is known of the effect of DOX treatment on NO 
production in skeletal muscle.  
 In skeletal muscle, the compartment separating the myocytes from the capillary 
network is known as the interstitial space.  The interstitial compartment plays a functional 
role in the regulation and integration of various substances including NO (Jackson, 2005; 
MacLean et al., 1999).  First introduced by Delgado et al. (Delgado et al., 1972), the 
microdialysis technique allows for the direct in vivo investigation of compounds located in 
the interstitial space.  To our knowledge, the effect of DOX administration on intracellular 
and interstitial concentrations of NO have not been examined.  These data would greatly 
advance our understanding in the role of DOX chemotherapy on NO production in skeletal 
muscle.   
As such, the purpose of the current study was simultaneously quantify intracellular 
and interstitial concentrations of NO in skeletal muscle as a result of the administration of 
DOX in order to provide insight in the possible mechanisms leading to muscle dysfunction.  
It is hypothesized that the administration of DOX will increase the intracellular and 
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interstitial concentrations of NO in skeletal muscle.  The major finding in this study was a 
DOX dose-dependent effect on intracellular and interstitial concentrations of NO which 
may affect ROS generation.  These data indicate that the effect of DOX on skeletal muscle, 
and more specifically NO production, may play a more significant role in the therapeutic 
impact of DOX chemotherapy than previously considered.  
 
8.3  Materials and Methods 
8.3.1  Animals 
All of the experimental procedures in the study were approved by the Laurentian 
University Animal Care Committee.  Male Sprague-Dawley rats (n=102, 434.3±8.3 g) 
were obtained from Charles River Laboratories (Senneville, QC) and were housed 
according to Standard Operating Procedures and Policies for the Housing and 
Environmental Enrichment of Rodents at the Laurentian University Animal Care Facility.  
Experiments began after a one week acclimation period. 
8.3.2  Pre-experimental procedures  
Experimental groups.  Rats were injected intraperitoneally (i.p.) with Doxorubicin 
(Doxorubicin Hydrochloride. Pfizer, Canada) at a dose of 1.5 mg/kg (Groups 1 to 8, n=6 
per group) or 4.5 mg/kg (Groups 9 to 16, n=6 per group).  A sham injection of saline 
solution was administered to a control group (i.p., n=3).  Once administered, rats were 
randomly grouped into experimental endpoints of 24, 48, 72, 96, 120, 144, 168 or 192 hrs. 
post-injection (Figure 1a).  Previous studies have examined the cardiotoxic effect of DOX 
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following the administration of various doses and dose regimens.  Based on these studies, 
the doses in the current study were selected in order to examine the acute effects of the 
drug on skeletal muscle NO production while minimizing the cardiotoxic potential.  Further 
details regarding the rationale is found in the Discussion. 
 
Figure 1:  (A) Schematic representation of the experimental protocol, indicating groups 
of rats receiving an injection of 1.5 mg kg-1 dose (groups 1-8) or 4.5 mg kg-1 (groups 9-
16) of DOX i.p.  A sham injection is administered to the control group (Ctrl). (B) 
Representation of the experimental proceedings for dialysate and tissue collection 
following microdialysis probe insertion.   
  
Microdialysis probes. A complete description of the construction of the 
microdialysis probes has previously been outlined (Hellsten et al., 1998). Briefly, 
microdialysis fibers were constructed using Spectra Microdialysis fibers (Spectrum, VWR 
International) with a molecular cutoff of 13 kDa and Polyamide-100II tubing 
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(MicroLumen, Tampa FL) cut to 9.5 and 5 cm lengths.  The ends of the fiber were inserted 
1 cm into the hollow polyamide tube and glued.  The exposed portion of the fiber 
(diffusible) between the polyamide tubes measured 1.0 cm in length.  Probe recovery was 
determined using an in vitro method previously described.   
8.3.3  Experimental procedures  
Animals. On the day of the experiment, the rat was placed into an induction 
chamber and anaesthetized with an EZ-150 vaporizer unit (EZ-Anesthesia, Euthanex 
Corporation, Palmer, PA), which blends oxygen (100% O2 Praxair, Sudbury, ON) and 
isoflurane at a rate of 5 %.  Once anaesthetized, the rat was removed from the chamber and 
placed onto a heated pad while its nose was placed into a nosepiece supplying a continuous 
delivery of oxygen and isoflurane (2-2.5 %).  The animal remained under anaesthesia 
throughout the experiment and the plane of anaesthesia was routinely checked by toe 
pinches.  Heart rate and oxygen saturation were monitored throughout the experiment using 
a pulse oximeter (SurgiVet) attached to the base of the tail.  Body temperature (between 
36–37oC) was maintained using a heated surgical bed (EZ-Anaesthesia) and a heating 
lamp.  Following the completion of the experiment, the animal was euthanized by 
decapitation.     
Probe insertion.  A schematic representation of the procedure for microdialysis 
probe insertion has previously been published by our research group (Fabris & MacLean, 
2015).  In short, incisions were made at the base of the leg using curved dissecting scissors 
and the skin was manually pulled back until the entire leg was exposed, the excess skin 
was then removed.  A 21 gauge curved cannula was inserted anteriorly into the muscle 
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along the muscle’s natural fibre orientation and acted as a guide for the microdialysis probe.  
Once the cannula was in place, the 9.5 cm portion of the probe is inserted caudally through 
the cannula and extended past the foot.  As soon as the diffusible portion of the probe was 
oriented into the muscle, then the 5 cm portion of the probe was held in place while the 
cannula was retracted out of the tissue leaving the probe in place. 
Experimental protocol. Two microdialysis probes were inserted into the hind limb 
for this experiment, one in the lateral gastrocnemius and one in the medial gastrocnemius 
muscle (n=2 probes per animal).  Following probe insertion, the fibers were perfused 
(model 102, CMA) at a rate of 3 µL/min with Ringer’s solution.  It is recognized that probe 
insertion results in some cellular disruption therefore traditionally a 60 min. equilibration 
period prior to the initiation of the experiment was used to insure that the external 
environment surrounding the probes had stabilized and all cellular damage had dissipated 
(MacLean et al., 2001). 
Following the equilibration period, the experimental protocol was initiated (Figure 
1b) where dialysate was collected for a period of 75 minutes in order to obtain sufficient 
volume that was required for analysis (225 µL total).  Dialysate samples were collected in 
microcentrifuge tubes and immediately sealed to prevent evaporation and stored at -80oC 
until analysis. It is important to note that due to the nature of the procedure, the exact 
placement of the diffusible portion of the probe within the limb is not determined with 
respect to exact fibre types surrounding the probe.  However is it common to describe the 
probe as being in a muscle group which predominantly expresses a fibre type.  Upon 
completion of dialysate collection, the plantaris (PL), soleus (SOL), medial gastrocnemius 
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(WG) and muscles were extracted, inserted into cryogenic vials, flash frozen in liquid 
nitrogen and stored at -80oC until analysis. 
8.3.4  Sample analysis 
Sample Preparation.  Frozen muscle samples were placed in a freeze drier (Freeze 
Drier 4.5, Labconco) at 10 microns Hg for 24 hrs. Subsequently, samples were powdered 
and tweezed free of all visible connective tissue.  
NO Analysis. Two mg of freeze dried skeletal muscle were added to 400 µL, 0.5 M 
perchloric acid for the extraction of protein.  These samples were vortexed for 5 min. and 
then homogenized for 5 min. using a Kontes Pellet Grinder.  The samples were then cooled 
on ice for 20 min. and centrifuged at 14 000 r.p.m. for 10 min. before analysis.  The 
collected dialysate samples represent an ultra-clean filtrate and did not require any pre-
analysis preparation.  NO concentrations in skeletal muscle and dialysate samples were 
determined by chemiluminescence using a Sievers Model 280i Nitric Oxide Analyzer.  
Vanadium chloride was used to convert nitrate and nitrite (NOx) to nitric oxide.  The 
reduction was done at 95oC in 0.1 M hydrogen chloride.  5 µL of the prepared skeletal 
muscle supernatant and dialysate samples were analyzed in duplicate and quantification of 
NO concentrations were determined in each sample by comparison with a standard curve 
(sodium nitrate). 
Arginine Analysis.  Two mg of freeze dried skeletal muscle were added to 100 µL 
purified water (EMD Millipore, USA) containing L-Norleucine (Sigma-Aldrich, USA) as 
internal standard then homogenized for 30 sec. using a Kontes Pellet Grinder.  The 
homogenate was then transferred into a centrifugal filtering tube (EMD Millipore, USA) 
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and centrifuged at 15 000 r.p.m. for 20 min.  20 µL of the filtrate was added to 60 µL borate 
buffer and 20 µL fluor reagent (AccQ-Tag, Waters Canada) and vortexed immediately for 
30 sec.  Samples were placed on a heating block at 55oC for 10 min. before analysis.  Arg 
concentrations were determined by HPLC using AccQ-Tag Amino Acid Analysis kits 
(Waters, Canada).  Quantification of Arginine was determined by comparison with a 
standard curve and corrected by internal standard. 
Statistics.  Changes in NO concentrations between time points and doses were 
analyzed using a two-way ANOVA.  When significant differences were indicated, a 
Tukey’s post hoc test was used to determine where the significance occurred.  Significance 
was accepted at P<0.05.  All values used in graphical representations are displayed as mean 
± SEM. 
 
8.4  Results 
The concentration of intracellular NO was higher (P<0.05) in the SOL 24 hrs. 
(1.25±0.15 mmol/kg dw) following the administration of 1.5 mg/kg DOX when compared 
to control (0.71±0.09 mmol/kg dw).  The administration of 4.5 mg/kg DOX resulted in 
lower (P<0.05) intracellular NO concentrations 24 and 48 hrs. (0.35±0.04 mmol/kg dw and 
0.48±0.04 mmol/kg dw, respectively) post-injection when compared to control (1.25±0.15 
mmol/kg dw).  When comparing between administered doses, intracellular  NO 
conentrations were higher (P<0.05) following the 1.5 mg/kg after 24 (357 %), 48 (171±9 
%), 168 (141±2 %) and 192 hrs. (122±2 %) when compared to the 4.5 mg/kg dose.  
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Concentrations of intracellular NO were higher after 96 (123±2 %) and 120 hrs. (136±6 
%) following the injectin of 4.5 mg/kg when compared to the 1.5 mg/kg dose (Figure 2a). 
Intracellular NO concentrations in the WG were not significantly altered at any time 
point by the administration of 1.5 mg/kg DOX.  However, the injection of 4.5 mg/kg DOX 
resulted in lower (P<0.05) intracellular NO concentrations after 24 (0.39±0.05 mmol/kg 
dw)  and 48 hrs (0.53±0.03 mmol/kg dw) as compared to control (0.89±0.09 μmol/kg dw).  
When comparing between treatments, the 4.5 mg/kg dose was lower (P<0.05) after 24 
(267±4 %) and 48 hrs. (149±1 %) when compared to the 1.5 mg/kg dose, however NO 
concentrations were higher (P<0.05) after 96 hrs. (125±8 %).  Furthermore, intracellular 
NO concentrations were higher (P<0.05) following the 1.5 mg/kg dose as compared to the 
4.5 mg/kg dose after 192 hrs. (117±3 %) (Figure 2b).   
The administration of either the 1.5 or 4.5 mg/kg did not affect NO concentrations 
in the PL when compared to control.  However when comparing between administered 
doses, the administration of 1.5 mg/kg resulted in higher (P<0.05) intracellular NO 
concentrations after 24 hrs. (133±9 %) compared to the 4.5 mg/kg dose.  Additionally, in 
comparison to the 1.5 mg/kg dose, intracellular NO was higher (P<0.05) following the 4.5 
mg/kg dose after 48 and 72 hrs (130±4 % and 131±6 %, respectively) (Figure 2c). 
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Figure 2:  Intracellular concentrations of nitric oxide, quantified using chemiluminescent 
analysis, in the (A)  Soleus, (B)  White gastrocnemius and (C)  Plantaris following the i.p. 
administration of 1.5 mg/kg DOX or 4.5 mg/kg DOX.  * Denotes significance compared 
to control.  α Denotes difference (P<0.05) between administered doses. 
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Interstitial NO concentrations were higher (P<0.05) 24, 48, 72, 96 and 120 hrs. 
(5.48±0.33, 7.06±0.17, 5.17±0.2, 10.11±0.62 and 6.77±0.26 μM, respectively) following 
the administration of 1.5 mg/kg DOX whem compared to control (2.94±0.36 μM).  
Surprisingly, interstitial NO was higher (P<0.05) after 96 hrs. (9.69±1.06 μM) post-
injection of 4.5 mg/kg DOX when compared to control (2.94±0.36 μM) while no other 
differences were observed throughout the course of the experiment.  When comparing 
between doses, interstitial concentrations of NO were increased (P<0.05) by 159±5 % after 
48 hrs. and 280±2 % after 120 hrs. following the 1.5 mg/kg compared to the 4.5 mg/kg 
dose.  However, NO concentrations were 234±6 % and 126 % higher (P<0.05) after 168 
and 192 hrs. subsequent to the 4.5 mg/kg administration when compared to the 1.5 mg/kg 
dose (Figure 3).  
 
Figure 3:  Skeletal muscle interstitial nitric oxide concentrations, quantified using 
chemiluminescent analysis, following the i.p. administration of 1.5 mg/kg DOX or 4.5 
mg/kg DOX.  * Denotes significance compared to control.  α Denotes significance between 
administered doses. 
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Intracellular concentrations of Arg were quantified in order to determine if the 
variations in NO concentrations were the result of substrate availability.  Following the 1.5 
mg/kg dose, Arg was significantly higher (P<0.05) in the SOL (12±3.6 mmol/kg dw) and 
72 hrs (14.5±8.9 mmol/kg dw) compared to control (6.2±0.2 mmol/kg dw).  The 4.5 mg/kg 
dose resulted in higher (P<0.05) concentrations of Arg after 120 hrs. (17.7±5.5 mmol/kg 
dw) compared to control (6.2±0.2 mmol/kg dw).  When comparing between administered 
doses, intracellular Arg was higher (P<0.05) following the 1.5 mg/kg dose after 24, 48 and 
72 hrs (242±41 %, 158±279 % and 122±19 % respectively) compared to the 4.5 mg/kg 
dose, however concentrations were significantly higher in the 4.5 mg/kg after 120 (161±72 
%) and 192 hrs. (124±4 %) (Figure 4a). 
In the WG, the administration of 1.5 mg/kg DOX resulted in higher (P<0.05) Arg 
concentrations after 24 hrs. (14.8±6.8 mmol/kg dw) compared to control (4.3±2.4 mmol/kg 
dw) while no significant differences were observed following the 4.5 mg/kg dose.  Between 
doses, Arg concentrations were higher (P<0.05) ) following the 1.5 mg/kg dose after 24 
and 168 hrs (320±94 % and 185±51 %, respectively) (Figure 4b). 
The administration of 1.5 mg/kg DOX resulted in higher intracellular 
concentrations of Arg in the PL after 24 hrs (24.3±1.7 mmol/kg dw) compared to control 
(5.6±1.3 mmol/kg dw) whereas the 4.5 mg/kg dose elevated intracellular Arg levels 72, 96, 
120 and 144 hours (13±2, 12.4±2.2, 13.4±2, 11.5±1.5 mmol/kg dw, respectively).  
However, when comparing doses, the 1.5 mg/kg dose increased (P<0.05) Arg 168±52 % 
compared to the 4.5 mg/kg dose after 168 hrs.  Arg was more elevated (P<0.05) following 
the 4.5 mg/kg dose after 192 hrs (145±12 %) compared to the 1.5 mg/kg dose (Figure 4c).   
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Figure 4:  Intracellular concentrations of L-Arginine, quantified by HPLC analysis, in the 
(A) Soleus, (B) White gastrocnemius and (C) Plantaris following the i.p. administration of 
1.5 mg/kg DOX or 4.5 mg/kg DOX.  * Denotes significance compared to control.  α 
Denotes significance between administered doses. 
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8.5  Discussion and Conclusion 
The purpose of the current study was to simultaneously examine intracellular and 
interstitial concentrations of NO in skeletal muscle following the administration of DOX.  
The major finding in this study was a DOX dose-dependent effect on NO concentrations 
in both the intracellular and interstitial spaces in skeletal muscle.  A persistent elevation 
(24-120 hrs.) in interstitial NO concentration was examined following the administration 
of 1.5 mg/kg DOX whereas an acute decrease (24-48 hrs.) in intracellular NO 
concentrations occured following the 4.5 mg/kg dose.  These apparent alterations in NO 
homeostasis may lead to significant physiological effects including increased local blood 
perfusion in the tissue, increased ROS generation and peroxynitrite formationThe elevation 
in interstitial NO and increased local blood pefusion may play a key role in the removal of 
the drug from the tissue.  By utilizing the microdialysis technique, we have simultaneously 
quantified for the first time the interstitial and intracellular concentrations of NO in skeletal 
muscle following DOX administration.  These data provide important insight in the 
possible mechanisms leading to DOX related skeletal muscle dysfunction.  
A well-documented side effect of DOX chemotherapy is a dose-dependent 
cardiotoxicity, which has been shown to lead to the onset of chronic cardiomyopathy and 
congestive cardiac failure (Kremer, van Dalen, Offringa, Ottenkamp, & Voute, 2001; 
Minotti et al., 2004; Paulides et al., 2006).  In human and animal models, the decrease in 
cardiac performance has been shown to increase iNOS expression in skeletal muscle 
(Okutsu et al., 2014; Riede, Forstermann, & Drexler, 1998).  In order to minimize the drug-
induced risk of cardiotoxicity in the current study, a single dose of low concentration (1.5 
mg/kg or 4.5 mg/kg) DOX was used.  Former studies have utilized a variety of 
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concentrations and treatment regimens documenting significant cardiomyocyte damage.  A 
single i.p. dose of 20 mg/kg (Iqbal et al., 2008) or 15 mg/kg (Nagi & Mansour, 2000) has 
resulted in cardiotoxicity whereas cardiomyocyte damage has not been observed as a result 
of a 10 mg/kg dose (Jensen et al., 1984).  Minor cardiomyocyte apoptosis was reported 3 
days following injection of 1.5 mg/kg and 5 mg/kg, however it remains unclear whether 
cardiac performance was significantly altered (Arola et al., 2000).  Cumulative doses have 
been studied where 1 mg/kg i.p. administered 15 times over 3 weeks resulted in cardiac 
dysfunction (Teraoka et al., 2000) and 1.5 mg/kg for 9 weeks resulted in severe 
cardiomyopathy (Guerra et al., 2005).  Much of the research regarding the effect of DOX 
administration on NO production has been focused on cardiomyocytes while the effect in 
skeletal muscle remains poorly understood.  While providing a dose-related experimental 
contrast, the concentrations used in the current study greatly minimize the possibility that 
changes in NO concentrations are not a result of drug related cardiotoxicity.   
It is apparent that the underlying mechanisms affecting the production of 
intracellular and interstitial NO differ between administered doses. Throughout the 
experiment, the administration of 1.5 mg/kg DOX did not have any sinigicant effect on the 
intracellular concentrations of NO however there was a persistent (24-120 hrs.) elevation 
of NO levels in the interstitial space.  Interestingly, the threefold increase in administered 
dose resulted in an acute (24-48 hrs.) decrease of intracellular NO while there was no 
significant effect on interstitial concentrations.  As a primary substrate required for the 
synthesis of NO by NOS isoforms, intracellular Arg concentrations were examined to 
determine if substrate availability was responsible for the apparent differences in NO 
concentrations.  In all muscle groups, intracellular concentrations of Arg sharply increased 
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24 hrs. following the administration of 1.5 mg/kg DOX then subsequently stabilized for 
the remainder of the experiment.  This acute increase would contribute to the incrase in NO 
production seen at the same time point (24 hrs.) however this would not account for the 
chronic elevation of NO observed 48-120 hrs.  No significant changes in Arg were observed 
following the 4.5 mg/kg dose with the exception of the PL where Arg was increased 72-
144 hrs. post injection.  Though, this did not result in a significant increase intraceulluar 
NO production within this muscle group.  Therefore, these data indicate that the differences 
in NO concentrations as a result of both administered doses is not the result of substrate 
availibility but may be the result of altered NOS activity.   
The effect of DOX on NOS isoforms has been studied in cancer cells, 
cardiomyocites and skeletal muscle.  The increase in interstitial NO observed in this study 
as a result of the 1.5 mg/kg dose is supported by previous research which have described 
the nuclear translocation of NF-κB leading to the upregulation and increased activity of 
iNOS as a result of DOX treatment (Riganti et al., 2005, Aldieri et al., 2002, Gilliam and 
St Clair, 2011).  Therefore, the increase in interstitial NO may be attributed to the increased 
iNOS activity and subsequent diffusion of NO into the extracellular space.  However, this 
mechanism does not describe the unexpected reduction of intracellular NO as a result of 
the 4.5 mg/kg dose.  The reduction of NO synthesis has previously been observed in bovine 
aortic endothelial cells (Kalivendi, Kotamraju, Zhao, Joseph, & Kalyanaraman, 2001), 
cardiac myocytes (Kotamraju, Konorev, Joseph, & Kalyanaraman, 2000; Sawyer, 
Fukazawa, Arstall, & Kelly, 1999) and colorectal cancer cells (Jung et al., 2002).  These 
studies describe that, eNOS transcription and activity is upregulated in the presence of 
DOX.  The binding of DOX to the eNOS reductase domain leads to the one-electron 
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reduction of DOX and subsequent formation of a DOX semiquinone radical.  As a result, 
the semiquinone activated redox cycling alters eNOS activity from NO synthesis to 
superoxide generator (Garner et al., 1999; Vasquez-Vivar et al., 1997).  In agreement with 
the aforementioned studies, the more elevated administered dosage of DOX may have 
increase the binding of the drug to eNOS ultimately reducing the intracellular 
concentrations of NO as seen in the current study.  Therefore, these data indicate that the 
changes in NO concentrations as a result of the administration of DOX may be the result 
of a dose dependent effect of DOX on NOS upregulation and activity.  
In skeletal muscle, the production of NO is highly regulated.  The dose dependent 
disruption in homeostasis seen in this study may lead to significant physiological 
ramifications.  The increase in interstitial NO, as seen following the 1.5 mg/kg dose, and 
subsequent diffusion of NO into neighboring smooth muscle cells activates guanylyl 
cyclase which then catalyzes the dephosphorylation of GTP to cGMP causing relaxation 
and increased local blood flow (Archer et al., 1994).  Also, it is well known that DOX 
generates high levels of oxidative stress in cardiomyocytes primarily attributed to its ability 
to disrupt the electron transport chain effectively resulting in the formation of ROS that 
includes superoxide and hydroxyl radicals (Conklin, 2004; Gille & Nohl, 1997).  NO 
strongly reacts with superoxides (O2-) to produce peroxynitrite (ONOO-) at a substrate 
diffusion-limited rate (Beckman, Beckman, Chen, Marshall, & Freeman, 1990; Evig et al., 
2004).  It is possible that the steady diffusion of NO into the interstitial space leading to a 
stable and elevated concentration, as seen in the current study, may increase the possibility 
of ONOO- formation.  Highly reactive, the diffusion of peroxynitrites back into the cell 
decreases mRNA levels of myoblast determination protein (MyoD) (Di Marco et al., 2005) 
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required for skeletal muscle differentiation (Megeney, Kablar, Garrett, Anderson, & 
Rudnicki, 1996).  Furthermore, the increase of iNOS expression and NO as well as 
peroxinitrite production has been shown to oxidize the conserved cysteine domain of 
transcription factor Jun-D (Buck & Chojkier, 1996).  The inhibition of Jun-D decreases 
muscle creatine kinase (MCK) expression, important for the maintenance of ATP reserves 
and muscle function (Buck & Chojkier, 1996; Ramamoorthy, Donohue, & Buck, 2009; 
Wallimann, Wyss, Brdiczka, Nicolay, & Eppenberger, 1992) (Figure 5a).  Furthermore, it 
is possible that the synergistic increase of iNOS and superoxide generation as a result of 
the effect of DOX on eNOS activity following the administration of 4.5 mg/kg DOX may 
amplify peroxynitrite formation and exacerbate the aforementioned physiological effects 
(Figure 5b).   
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Figure 5:  The effect of 1.5 mg/kg i.p. (A) and 4.5 mg/kg i.p. (B) Doxorubicin 
administration on nitric oxide (NO) production in the intracellular and interstitial space of 
skeletal muscle.  (A) The upregulation of inducible nitric oxide synthase (iNOS) by 
Doxorubicin (DOX) increases intracellular (IC) NO production and subsequent diffusion 
of NO into the interstitial space (ISS).  NO strongly reacts with superoxides (O2-) in the 
interstitial space to produce peroxynitrites (ONOO-).  The diffusion of ONOO- back into 
the cell decreases mRNA levels of myoblast determination protein (MyoD) and decreases 
muscle creatine kinase (MKC) expression via transcription factor Jun-D inhibition.  (B) 
The effect of 4.5 mg/kg i.p. Doxorubicin administration on nitric oxide production in the 
intracellular and interstitial space of skeletal muscle.  The upregulation of iNOS by DOX 
increases IC NO production.  Concurrently, DOX binds to the reductase domain of eNOS 
altering its activity from NO production to O2- generator.  The diffusion of NO into the ISS 
reacts with O2- in the interstitial space to produce ONOO- which may diffuse back into the 
cell.  ONOO- formation in the cell is further exacerbated by the DOX/eNOS derived 
increase in IC O2-, which decreases mRNA levels of MyoD and decreases MKC expression 
via transcription factor Jun-D inhibition.  
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The reduction of DOX and subsequent formation of a semiquinone metabolite by 
eNOS (Garner et al., 1999; Vasquez-Vivar et al., 1997) may play a more significant role in 
the metabolic breakdown of DOX than previously considered.  It is well established that 
aldo-keto reductase (AKR) and carbonyl reductase (CBR) activity is primarily responsible 
for the systemic breakdown of DOX (Kassner et al., 2008; Lim et al., 2013).  To our 
knowledge AKR expression in skeletal muscle remains to be determined whereas as a 
lower affinity of CBR has been shown (Kassner et al., 2008).  Much of the attention 
regarding the reduction of DOX to its semiquinone metabolite by eNOS is focused on the 
generation of ROS.  However, when considering the apparent sequestering of DOX in 
skeletal muscle (Fabris & MacLean, 2015) and constitutive expression of eNOS (Stamler 
& Meissner, 2001), eNOS may play a more prominent role in the metabolic breakdown of 
DOX than aldo-keto and carbonyl reductases. The current study not only supports our 
previous notion suggesting the active role skeletal muscle on DOX availability and 
metabolism but provides insight into the possible physiological mechanisms involved.   
This study demonstrates for the first time the effect of DOX administration on 
intracellular and interstitial NO concentrations simultaneously in skeletal muscle, 
highlighting the possible mechanisms leading to myocyte toxicity before that of a 
cumulative and dose-dependent cardiotoxicity.  Additionally, the potential role of NO 
production and NOS expression in skeletal muscle and its role in the systemic availability 
of DOX is hypothesized.  Overall, the effects of DOX on skeletal muscle may play a more 
important role than previously considered as NO mediation is an important factor in the 
quality of life and recovery of patients receiving DOX therapy. 
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CHAPTER IV 
(Study 3) 
Amino Acid Metabolism in Skeletal Muscle Following the Administration of 
Doxorubicin Chemotherapy 
 
9.  Study 3 Objective: Investigate the amino acid response in skeletal muscle following 
the administration of Doxorubicin. 
 
10.  Overview of Study 3 
The availability of intracellular amino acids is essential for the health and 
maintenance of skeletal muscle.  Intramuscular amino acids derive from the exchange with 
the vasculature or from the endogenous breakdown of proteins from within the tissue.  A 
net increase or decrease in total amino acid concentrations is strongly indicative of 
metabolic states favoring protein degradation or synthesis, respectively.  The preceeding 
chapters have shown that DOX remained sequestered in skeletal muscle and that the 
sequestering of the drug in the tissue affected the production of a key local vasodilatory 
melocule.  The current chapter examines the effect of DOX retention in skeletal muscle on 
the intramuscular total amino acid pool.  By concurrently investigating the vacular, 
interstitial and intramuscular total amino acid concentrations, unique insight into the 
response of amino acids in communicating compartments was be obtained.  The resulting 
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data provides a substantial foundation for future studies focused  on the effect of DOX on 
amino acid metabolism in skeletal muscle.   
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11.1  Abstract 
Skeletal muscle (SM) health and integrity is dependent on the dynamic balance 
between protein synthesis and degradation, central to this process is the availability of 
amino acids (AA) in the free amino pool. Doxorubicin (DOX) remains one of the most 
widely used chemotherapeutic agents for the treatment of solid tumors and hematological 
malignancies.  While its clinical use is constrained by a well-documented cardiotoxic side 
effect, little is known of the effect of the drug on SM.  The purpose of the study was to 
examine the effect of DOX administration on intracellular, interstitial and vascular 
concentrations of AA in SM of the rat up to 8 days after the administration of a 1.5 or 4.5 
mg/kg i.p. dose.  Intracellular total amino acids (TAA), essential amino acids (EAA) and 
branched-chain amino acids (BCAA) where significantly increased in each muscle group 
analyzed, following the 1.5 and 4.5 mg/kg doses compared to control.  In the plasma, TAA 
were significantly increased compared to control where greater (P>0.05) concentrations 
were observed following the 1.5 mg/kg dose compared to the 4.5 mg/kg dose.  Compared 
to control, the 1.5 mg/kg dose resulted in an increase (P<0.05) in interstitial TAA whereas 
the 4.5 mg/kg resulted in a sustained decrease (P<0.05).  This study provides important 
insight into the amino acid response following DOX chemotherapy and presents a 
substantial foundation for future studies focused on reducing (SM) damage and recovery 
by targeting amino acid metabolism. 
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11.2  Introduction 
Skeletal muscle represents the largest organ in the human body, composing ~40% 
of the total body weight and in addition to its mechanical function, skeletal muscle plays a 
key role in whole body metabolism (Felig, 1973; Wolfe, 2006).  Muscle mass is dependent 
on the dynamic balance between protein synthesis and degradation, and central to this 
process is the availability of amino acids in the free amino acid pool.  In the human body, 
approximately 130 gms of free amino acids are present in the skeletal muscle intracellular 
space (Wagenmakers, 1998) and, in addition to its role in muscle protein turnover, amino 
acids participate in numerous metabolic reactions that take place in tissues throughout the 
body.  Perturbation in the dynamic balance between protein synthesis and degradation 
where net protein breakdown is greater than that of synthesis in skeletal muscle can result 
in a cachectic, or muscle wasting, condition.   
Cachexia is a serious, life-threatening condition associated with several pathologies 
including cancer (Esper & Harb, 2005; K. C. Fearon et al., 2012; Porporato, 2016).  Cancer 
cachexia affects 50-80% of cancer patients and accounts for approximately 20% of cancer-
related deaths (Argiles et al., 2014; Tisdale, 2002).  Cachectic patients with greater than 
15% weight loss exhibit impaired physiological function and a drastic reduction in quality 
of life.  Patient death normally occurs when weight loss exceeds 30% (Tisdale, 2002).  
Additionally, cachectic patients are less tolerant to chemotherapy, radiation therapy and the 
response to these therapeutic strategies are significantly reduced (K. C. Fearon & Baracos, 
2010; Vaughan et al., 2013).  The use of anti-cancer chemotherapeutics such as that of 
Doxorubicin may play a role in the onset of cachexia in cancer patients undergoing 
chemotherapy. 
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Doxorubicin (DOX) remains one of the most widely used chemotherapeutic agents 
for the treatment of solid tumors and hematological malignancies (Weiss, 1992).  DOX 
induced cytotoxicity has been attributed to DNA intercalation, inhibition of topoisomerase 
II (TOP2A) and the formation of reactive oxygen species (Minotti et al., 2004; Momparler 
et al., 1976; S. Wang et al., 2004). The clinical use of DOX is constrained by a well 
described dose-dependent and cumulative cardiotoxic side effect leading to the 
development of congestive heart failure (Lefrak et al., 1973; Singal & Iliskovic, 1998).  
DOX-related cardiotoxicity has been shown to be mediated by its primary circulating 
metabolite, Doxorubicinol (DOXol).   
Recent research conducted in our laboratory has quantified the previously 
unreported sequestering of DOX and DOXol in skeletal muscle and described the 
relationship between the muscular, interstitial and vascular compartments following the 
administration of DOX (Fabris & MacLean, 2015).  In skeletal muscle, the interstitial space 
represents an important active compartment located between the vasculature and the tissue 
and it has been shown to play a functional role in the regulation and integration of various 
metabolic substances.  The microdialysis technique, first described by Delgado et al. 
(Delgado et al., 1972), provides a unique opportunity to quantify the availability of amino 
acids in this compartment in vivo.   
The importance of skeletal muscle health and integrity on the positive prognosis 
and quality of life of a cancer patient is well known however the effect of chemotherapy 
on skeletal muscle has been relatively overlooked.  Therefore, the purpose of the present 
study was to examine the effects of DOX administration on the intramuscular, interstitial 
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and vascular concentrations of amino acids in an effort to delineate the effects of DOX on 
protein turnover.  
 
11.3  Materials and Methods 
11.3.1  Animals 
The experimental procedures performed in this study were approved by the 
Laurentian University Animal Care Committee.  Male Sprague-Dawley rats (n=106, 
434±60 gms) were obtained from Charles River Laboratories (Senneville, QC) and were 
housed and fed a 22/5 rodent diet (Envigo, WI, USA) according to Standard Operating 
Procedures and Policies for the Housing and Environmental Enrichment of Rodents at the 
Laurentian University Animal Care Facility.  Experiments began following a one-week 
acclimation period. 
11.3.2  Pre-experimental procedures  
Experimental groups.  The rats were placed into an induction chamber and 
anaesthetized with an EZ-150 vaporizer unit (EZ-Anesthesia, Euthanex Corporation, 
Palmer, PA), which blends oxygen (100% O2 Praxair, Sudbury, ON) and isoflurane at a rate 
of 5 %.  Once anaesthetized, the rats were removed from the chamber and placed onto a 
heated pad where nosepieces supplied a continuous delivery of oxygen and isoflurane (2-
2.5 %).  While under anaesthesia, the rats were injected intraperitoneally (i.p.) with 
Doxorubicin (Doxorubicin Hydrochloride. Pfizer, Canada) at a dose of 1.5 mg/kg (Groups 
1 to 8) or 4.5 mg/kg (Groups 9 to 16).  The administration of DOX followed an approved 
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injections SOP for Laurentian University.  A sham injection of saline solution was 
administered to a control group (i.p., n=10).  Once administered, rats were randomly 
grouped into experimental endpoints (n=6) of 24, 48, 72, 96, 120, 144, 168 or 192 hrs. 
post-injection (Figure 1a).  
 
Figure 1.  Schematic representation of the experimental groups and experimental 
procedures.  (A) Representation of the experimental groups receiving an injection of 1.5 
mg/kg dose (groups 1-8) or 4.5 mg/kg (groups 9-16) of DOX administered i.p.  A sham 
injection is administered to the control group (Ctrl). (B) Representation of the 
experimental proceedings for dialysate, blood and tissue collection following 
microdialysis probe insertion and carotid artery cannulation.  
 
Microdialysis probes. A complete description of the construction of the 
microdialysis probes has previously been outlined (MacLean, LaNoue, Gray, & Sinoway, 
1998). Briefly, microdialysis fibers were constructed using Spectra Microdialysis fibers 
(Spectrum, VWR International) with a molecular cutoff of 13 kDa and Polyamide-100II 
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tubing (MicroLumen, Tampa FL) cut to 9.5 and 5 cm lengths.  The ends of the fiber were 
inserted 1 cm into the hollow polyamide tube and glued.  The exposed portion of the fiber 
(diffusible) between the polyamide tubes measured 1.0 cm in length.   
11.3.3  Experimental procedures  
Animals. On the day of the experiments, the rats were placed into an induction 
chamber and anaesthetized as described above. The animals remained under anaesthesia 
throughout the experiment and the plane of anaesthesia was routinely checked by toe 
pinches.  Heart rate and oxygen saturation were monitored throughout the experiment using 
a pulse oximeter (SurgiVet) attached to the base of the tail.  Body temperature (between 
36–37oC) was maintained using a heated surgical bed (EZ-Anaesthesia) and a heating 
lamp.  Following the completion of the experiment, the animals were euthanized by 
decapitation.     
Probe insertion.  Using curved dissecting scissors, incisions were made at the base 
of the leg and the skin was manually pulled back until the entire leg was exposed, the excess 
skin was then removed.  A 21 gauge curved cannula was inserted anteriorly into the muscle 
along the muscle’s natural fibre orientation and acted as a guide for the microdialysis probe.  
Once the cannula was in place, the 9.5 cm portion of the probe is inserted caudally through 
the cannula and extended past the foot.  As soon as the diffusible portion of the probe was 
oriented into the muscle, then the 5 cm portion of the probe was held in place while the 
cannula was retracted out of the tissue leaving the probe in place. 
Experimental protocol. Four microdialysis probes were inserted into a single hind 
limb for this experiment, two in the lateral gastrocnemius and two in the medial 
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gastrocnemius muscle (n=4 probes per animal).  Following probe insertion, the fibers were 
perfused (model 102, CMA) at a rate of 3 µL/min with Ringer’s solution.  It is recognized 
that probe insertion results in some cellular disruption therefore traditionally a 60 min. 
equilibration period prior to the initiation of the experiment was used to insure that the 
external environment surrounding the probes had stabilized and all cellular damage had 
dissipated (MacLean et al., 2001).  Subsequently, the skin and tissue covering the left 
carotid artery was removed. A 20 gauge cannula was inserted into the exposed artery and 
sutured in place. Heparinized saline (100 μL) was injected into the artery to maintain 
patency in preparation for blood sampling. 
Following the equilibration period, the experimental protocol was initiated (Figure 
1b) where dialysate was collected for a period of 75 minutes in order to obtain sufficient 
volume that was required for analysis.  Dialysate samples were collected in microcentrifuge 
tubes and immediately sealed to prevent evaporation and stored at -80oC until analysis.  
Arterial blood samples were collected during the collection of dialysate at 0, 35 and 75 
minutes. Samples were spun at 15,000 rpm for 25 seconds, plasma was separated and stored 
at -80°C until analysis.  Upon completion of dialysate and blood collection the plantaris 
(PL), soleus (SOL), medial gastrocnemius (WG) and muscles from the contralateral leg 
used for microdialysis were excised, inserted into cryogenic vials, flash frozen in liquid 
nitrogen and stored at -80oC until analysis. 
11.3.4  Sample analysis 
Skeletal Muscle. Frozen muscle samples were placed in a freeze drier (Freeze Drier 
4.5, Labconco) at 10 microns Hg for 24 hrs. Subsequently, samples were powdered and 
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tweezed free of all visible connective tissue.  Two mg of freeze dried skeletal muscle were 
added to 100 µL purified water (EMD Millipore, USA) containing L-Norleucine (Sigma-
Aldrich, USA) as internal standard then homogenized for 30 sec. using a Kontes Pellet 
Grinder.  The homogenate was then transferred into a centrifugal filtering tube (EMD 
Millipore, USA) and centrifuged at 15 000 r.p.m. for 20 min.  20 µL of the filtrate was 
added to 60 µL borate buffer and 20 µL fluor reagent (AccQ-Tag, Waters Canada) and 
vortexed immediately for 30 sec.  Samples were placed on a heating block at 55oC for 10 
min. before analysis.   
Plasma. Plasma samples were transferred into a centrifugal filtering tubes (EMD 
Millipore, USA) and centrifuged at 15 000 r.p.m. for 20 min.  20 µL of the filtrate was 
added to 60 µL borate buffer and 20 µL fluor reagent (AccQ-Tag, Waters Canada) and 
vortexed immediately for 30 sec.  Samples were placed on a heating block at 55oC for 10 
min. before analysis. 
Dialysate. The collected dialysate samples represent an ultra-clean filtrate and did 
not require any pre-analysis preparation.  As such, 20 µL of dialysate was added directly 
to 60 µL borate buffer and 20 µL fluor reagent (AccQ-Tag, Waters Canada) and vortexed 
immediately for 30 sec.  Samples were placed on a heating block at 55oC for 10 min. before 
analysis.  
Amino Acid Quantification. Amino Acid concentrations were determined by HPLC 
(Waters e2695, 2475 Fluorescence Detector, Waters Corporation) using AccQ-Tag Amino 
Acid Analysis kits (Waters, Canada).  Derivatized standards include aspartate, serine, 
glutamate, glycine, histidine, ammonia, arginine, threonine, alanine, proline, cysteine, 
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tyrosine, valine, methionine, lysine, isoleucine, leucine and phenylalanine. Quantification 
of amino acids were determined by comparison with a standard curve and skeletal muscle 
amino acids where corrected by internal standard. 
Statistics.  Changes in amino acid concentrations between time points and doses 
were analyzed using a two-way ANOVA.  When significant differences were indicated, a 
Tukey’s post hoc test was used to determine where the significance occurred.  Significance 
was accepted at P<0.05.  All tabled values and values used in graphical representations are 
displayed as mean ± SEM. 
 
11.4  Results 
Since the direction of all the individual amino acids following the administration of 
DOX are similar, changes in the amino acid pool will be described via changes in total 
amino acids. essential amino acids and branched-chain amino acids.  The total amino acids 
(TAA) include Asp, Ser, Glu, Gly, His, Arg, Thr, Ala, Pro, Cys, Tyr, Val, Met, Lys, Iso, Leu 
and Phe.  The essential amino acids (EAA) in the rat are His, Arg, Thr, Val, Met, Lys, Iso, 
Leu, Phe and branched-chain amino acids (BCAA) are Val, Iso and Leu.  It must be noted 
that Phe could not be quantified in the intramuscular samples due analytical limitations.  
Additionally, intramuscular and interstitial Arg data has previously been published (Fabris 
& MacLean, 2016).   
The administration of the 1.5 and 4.5 mg/kg DOX resulted in a dose-related 
difference in arterial plasma amino acid concentrations (Table 1).  Circulating arterial 
concentrations of TAA (Figure 2) and EAA were increased (P<0.05) as a result of either 
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administered dose compared to control however the increase in both the TAA and EAA 
were greater (P<0.05) following the 1.5 mg/kg dose compared to the 4.5 mg/kg dose.  
Circulating BCAA concentrations were significantly increased following the 
administration of both 1.5 and 4.5 mg/kg dose compared to control and were further 
elevated (P<0.05) at 96 hrs in the 4.5 mg/kg treatment group compared to the 1.5 mg/kg 
group.  Although Ser, Cys, and Lys were increased (P<0.05) compared to control, their 
concentrations were not significantly different when compared between administered 
doses.  Additionally, there were no changes in ammonia throughout the experiment 
following either administered dose.   
The administration of DOX resulted in a dose-related difference in interstitial 
amino acids (Table 2).  The 1.5 mg/kg dose resulted in a transient increase (P<0.05) in TAA 
(Figure 2), EAA and BCAA as well as ammonia from 24-96 hrs compared to control.  
However Cys, Lys and Leu decreased (P<0.05) to concentrations lower than control after 
96 hrs.  TAA, EAA, BCAA and ammonia decreased (P<0.05) 24-192 hours following the 
administration of 4.5 mg/kg DOX as compared to control.  Ser and Glu concentrations 
were increased (P<0.05) compared to control and Met was not significantly affected.   
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Figure 2:  Total amino acid concentrations in the (A) Plasma, (B) Dialysate, (C) White 
gastrocnemius, (D) Plantaris and (E) Soleus following the i.p. administration of 1.5 
mg/kg DOX or 4.5 mg/kg DOX.  * Denotes significance compared to control.  α Denotes 
difference (P<0.05) between administered doses. 
 
In the WG (Table 3), the administration of 1.5 and 4.5 mg/kg DOX increased 
(P<0.05) TAA (Figure 2) and EAA concentrations.  BCAA were significantly increased 
from 48-192 hrs following the 1.5 mg/kg dose whereas the 4.5 mg/kg dose increased 
(P<0.05) BCAA 48-120 hrs compared to control (Figure 3).  Following the 1.5 mg/kg dose, 
Cys significantly decreased compared to control and was undetectable after 72 hrs.  
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Concentrations of Asp, Ser, Ala, Pro, Iso and Leu where greater after the 1.5 mg/kg dose 
compared to the 4.5 mg/kg dose and ammonia was unaffected in both treatment groups. 
TAA (Figure 2) and EAA concentrations were significantly increased in the PL 
(Table 4) as a result of both doses as compared to control.  BCAA increased (P<0.05) from 
48-192 hrs and 24-120 hrs following the administration of 1.5 and 4.5 mg/kg DOX 
compared to control, respectively (Figure 3).  Ser increased (P<0.05) whereas Cys 
decreased (P<0.05) following the 1.5 mg/kg dose.  Significant increases in Ser, Pro, Val, 
Lys, Iso and Leu were observed following the 4.5 mg/kg dose compared to control.  His, 
ala, Pro, Val, Lys, Iso and Leu concentrations were more elevated (P<0.05) in the 1.5 mg/kg 
compared to 4.5 mg/kg treatment groups however Cys was significantly more elevated in 
the 4.5 mg/kg dose group.  Ammonia was unaffected throughout the experiment.    
SOL (Table 5) TAA (Figure 2) and EAA concentrations were significantly increased 
as a result of both administered doses of DOX.  Intramuscular BCAA concentrations where 
increased (P<0.05) after 48 hrs following the administrations of the 1.5 m/kg dose 
compared to control and remained elevated for the remainder of the experiments.  BCAA 
were increased (P<0.05) 24-144 hrs following the administration of 4.5 mg/kg DOX 
compared to control (Figure 3).  The 4.5 mgs/kg dose of DOX resulted in a transient 
increase (P<0.05) in Asp, Gly, His, Lys, Iso and Leu compared to control and subsequently 
returned to baseline.  Asp, Gly, His, Lys, Iso and Leu concentrations were higher following 
the 1.5 mg/kg  compared to the 4.5 mg/kg dose of DOX.  No significant changes in 
concentrations of ammonia were observed.  
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Figure 3:  Total intracellular concentrations of branched-chain amino acids (Val, Iso and 
Leu) in the (A) White gastrocnemius, (B) Plantaris and (C)  Soleus following the i.p. 
administration of 1.5 mg/kg DOX or 4.5 mg/kg DOX.  * Denotes significance compared 
to control.  α Denotes difference (P<0.05) between administered doses. 
 
11.5  Discussion and Conclusion 
The purpose of the current study was to examine the effects of DOX administration 
on amino acid concentrations in skeletal muscle, the interstitial space and the vasculature.  
The major findings were an observed increase in intramuscular  TAA, EAA and BCAA 
concentrations, strongly suggesting that the administration of DOX resulted in a net 
increase in protein degradation.  In addition, a dose-related difference was observed in the 
circulating concentration of amino acids where a greater increase was established following 
the administration of the 1.5 mg/kg dose of DOX compared to the 4.5 mg/kg dose.  The 
current study provides novel insights into the response of amino acids in skeletal muscle 
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and their subsequent concentrations in communicating compartments through the 
insterstitial space and into the circulation following the administration of DOX.   
The net change in amino acids in the tissue is indicative of the balance between 
synthesis or degradation state of proteins in the muscle.  The persistent three-fold increase 
in total intramuscular amino acids observed in the current study as a result of either 
administered dose of DOX strongly suggests that the rate of protein degradation was 
greater than that of protein synthesis.  This is further substantiated by a similar increase in 
intramuscular EAA concentrations as a result of either dose of drug administered.  De novo 
synthesis of EAA in the muscle is not possible and changes in intramuscular concentrations 
must come from the exchange with the vasculature or from the endogenous breakdown of 
protein within the tissue (T.E. Graham, 1995).  Of the EAA, the branched-chain amino 
acids (BCAA) Val, Iso and Leu are the dominant essential amino acids oxidized in skeletal 
muscle.  Therefore, any change in BCAA concentrations will most likely indicate a change 
in overall protein balance within the tissue.  
The metabolic effects of BCAAs in skeletal muscle, which range from nitrogen 
homeostasis to energy production and protein synthesis, are well described (Brosnan & 
Brosnan, 2006; Cole, 2015; T.E. Graham, 1995; MacLean et al., 1994).  In the current 
study, both the 1.5 and 4.5 mg/kg doses of DOX resulted in an increase in the intramuscular 
BCAA concentrations.  The mitochondrial branched-chain amino acid aminotransferase 
(BCAT) isoenzyme is primarily repsonbile for initiating BCAA catabolism (T. R. Hall et 
al., 1993).  The activity of the BCAT which transfers an amino group from BCAA to α-
ketoglutarate to form branched-chain ketoacids (BCKA) and Glu, responds rapidly to 
increases in intramuscular BCAA concentrations (Milan, 2011).  The increase in Glu 
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synthesis is indicative of BCAT activity and formation of BCKAs.  BCKA undergo 
irreversible oxidative decarboxylation by activated BCKA dehydrogenase complex 
(BCKAD) completing the the metabolism of leu (acetoacetate, acetyl-CoA), iso 
(propionyl-CoA, acetyl-CoA) and val (succinyl-CoA) for use in the TCA cycle (Cole, 
2015).   
The administration of 1.5 mg/kg DOX resulted in a substantial increase in BCAA 
in each muscle group whereas a transient increase was observed following the 4.5 mg/kg 
dose depending on the muscle group.  The underlying mecahnisms responsible for the dose-
related effect observed remains unclear.  However, there is strong evidence to suggest that 
the increase in intramuscular BCAA is not due to a reduction in the rate of transamination 
by BCAT, which is not regulated by end-product inhibition or phosphorylation-dependent 
activation of inactivation mechanisms.  This is made evident by the increase in Glu and 
Ala synthesis observed throughout the study. 
In skeletal muscle, Glu is the key metabolic precursor for the synthesis of Ala and 
Gln via Ala aminotransferase and Gln synthase, respectively (T. E. Graham, Sgro, Friars, 
& Gibala, 2000).  Ammonia detoxification in the muscle involves the safe transport of 
amino nitrogen, by Ala and Gln, to the liver for conversion to urea and subsequent excretion 
through the kidneys.  Ala was increased in both the muscle and in the circulation which is 
consistent with previous research demonstrating the oxidation and release of Ala with 
enhanced supply of BCAA (Ruderman & Berger, 1974).  Due to analytical limitations, Gln 
concentrations could not be determined, however no consistent changes in circulating or 
intracellular ammonia were observed irrespective of the administered dose suggesting that 
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the ammonia load was sufficiently managed via the increase in other disposal patways thus 
maitaining nitrogen homeostasis.   
The anabolic effect of BCAAs on protein metabolism is well established.  The 
mamalian target of rapamycin (mTOR) is a highly conserved serine-threonien kinase 
comprised of two disctinct mutiprotein complexes mTORC1 and mTORC2 (Catania et al., 
2011; M. N. Hall, 2008).  The mTORC1 complex includes mTOR, Raptor, Deptor, 
PRAS40 and mLST8/GβL.  Intramuscular amino acid availability increases levels of Ca2+ 
which activates mTORC1 signaling via ca2+/calmodulin-mediate actiavtion of PI3K 
(Gulati et al., 2008; Nobukuni et al., 2005).  The potent BCAA-mediated stimulation of 
protein synthesis has been primarily attributed to the Leu regulated activation of mTORC1 
by inducing the interaction of Ras-related GTP-binding protein (Rag) with ras-homolog 
enriched in the brain (Rheb) (Kimball & Jefferson, 2006; Norton & Layman, 2006).    
Recently, it has been reported that DOX causes insulin resistance mediated by AMPk 
inhibition  (de Lima Junior et al., 2016).  Additionally, it has been shown that Leu activation 
of mTOR is partially dependant on insulin (Kimball & Jefferson, 2006).  Taken together, it 
is possible that mTOR activity is stunted by the sum of these effects resulting in a decrease 
in protein synthesis.   
Collectively, the current study shows that the administration of DOX did not affect 
BCAA availability and has increased intramuscular BCAA concentrations.  The subsequent 
increases in Glu and Ala indicate that the enzymatic metabolism of BCAA has not been 
affected.  Furthermore, it is clear that the possible reduction in mTOR activity does not 
fully account for the increase in TAA observed in this study and that proteolysis may play 
a more prominent role. 
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Since its first clinical trials, DOX has been lauded as a highly effective anti-cancer 
chemotherapeutic. The fundamental concern with DOX chemotherapy, as is with most 
chemotherapeutic agents, is the systemic distribution of the drug following its 
administration.  Previous research from our laboratory has demonstrated that DOX and 
DOXol is sequestered and retained in skeletal muscle under the same experimetal 
conditions as those used in the current study (Fabris & MacLean, 2015).  Once in the cell, 
DOX intercalates between DNA base pairs effectively disrupting cell replication.  (Minotti 
et al., 2004; S. Wang et al., 2004).  It is possible that the integration of the drug in DNA 
may equally cause disruption in the unfolding of DNA and utimately disturbing or 
inhibiting protein synthesis and significantly contributing to the increase in intramuscular 
amino acid concentrations.  The effect of DOX on regulatory mechanisms responsible for 
the proper formation of proteins has been studied.  Recent research by Narandrula et al. 
(Narendrula et al., 2016) have shown that DOX capably induced rRNA disruption in 
cultured cells, suggesting that the formation of ROS and production of TNFα are likely 
factors responsible for the degradation of rRNA.  Additionally, White and colleagues 
(White-Gilbertson, Kurtz, & Voelkel-Johnson, 2009) have reported that DOX affects the 
phosphorylation of elongation factor 2 (EF-2), a key enzyme in the modulation of protein 
elongation during synthesis, and capably affects the rate of translation (Ryazanov & 
Davydova, 1989).  Furthermore, Lu et al. (Lu et al., 2011) have reported that DOX inhibits 
glucose-regulated protein 78 (GRP78) leading to the inactivation of  unfolded protein 
response (UPR) and subsequent proteolysis via protease activity.  The proteolytic outcome 
of protease activation may be the primary factor responsible for the significant increase in 
intramuscular TAA observed in this study.   
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Overall, the present study demonstrates that the administration of DOX increased 
intramuscular concentrations of BCAA which is not attributed to a reduction in BCAT 
activity and that the effect of the drug on BCAA-mediated protein synthesis alone does not 
account for the significant increase in intramuscular TAA.  Seemingly, the disruption of 
protein synthesis by direct and indirect effects of DOX influences the dynamic balance 
between protein degradation and synthesis to favor the former over the latter.   The resulting 
net protein breakdown is supported by the three-fold increase in intramuscular TAA and 
EAA concentrations. 
Plasma concentrations of amino acids are a balance between production and 
elimination.  Without ingestion, the largest shift in plasma amino acid concentrations come 
from changes in skeletal muscle protein turnover.  As discussed above, the rate of protein 
degradation was greater than that of protein sythesis resulting in an increase of 
intramuscular TAA following the administration of the drug.  The significant increase 
plasma TAA, where greater concentrations were observed following the 1.5 mg/kg dose 
compared to the 4.5 mg/kg dose of DOX, strongly indicates that the efflux of amino acid 
concentrations from the intramuscular pool into circulation were greater than that of 
systemic uptake resulting in the observed increase of arterial TAA.  
The diffusion of amino acids between the tissue and vascular compartment must 
pass through the interstitial space (ISS).  The interstitial compartment plays a functional 
role in the regualtion and integration of various endogenously produced metabolic 
substances (Leuenberger et al., 2008; MacLean, Sinoway, et al., 1998).  The current data 
demonstrate, for the first time, the effect of chemotherapy on interstitial amino acid 
concentrations.  Fabris and MacLean (Fabris & MacLean, 2015) recently measured and 
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sicussed the presence of DOX in the interstital space.  Interestingly, in the present study, 
an inverse relationship was observed between doses and the ISS concentrations of TAA.  
For example the 1.5 mg/kg dose of DOX resulted in a significant increase of TAA  in the 
ISS compared to control whereas the 4.5 mg/kg dose resulted in a sustained decrease when 
compared to control.  The increase in TAA concentrations followed by the eventual decline 
back to baseline is consistent with the rapid efflux of TAA out of the tissue and into the 
interstital compartment followed by a gradual uptake from the vasculature.  The decrease 
of TAA in the ISS following the 4.5 mg/kg dose may be the result of secondary effects of 
the drug on trasporter proteins responsible for the flux of amino acids out of the tissue and 
into the ISS or from the ISS into the vasculature.  The mediation of amino acid uptake and 
efflux from the myocyte is regulated by the expression of the several transporter proteins 
encoded by the SLC superfamily (Hyde, Taylor, & Hundal, 2003; Taylor, 2014).  The 
difference between the 1.5 and 4.5 mg/kg dose may be the result of higher concentrations 
of DOX affecting the normal function of the transporter proteins.  This is supported by our 
finding that lower concentrations of TAA were observed in the ISS and in the plasma as a 
result of the 4.5 mg/kg dose compared to the 1.5 mg/kg dose.  No studies have been 
conducted that have shown that an increase in DOX interferes with the normal function of 
the various transporter proteins associated with amino acid transport in skeletal muscle.  
Additionally, the systemic effect of the 4.5 mg/kg dose on other tissues would help explain 
the lower increase of TAA in the plasma when compared to the 1.5 mg/kg dose.  Therefore, 
in addition to a dose-related increase of plasma TAA, the study of the interstitial space by 
way of microdialysis has revealed a possible dose-related effect of DOX on amino acid 
transport mechanisms from skeletal muscle compartment into the vasculature.   
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This study describes for the first time the concurrent concentrations of amino acids 
in skeletal muscle, the interstitial space and the vascular compartment following the 
administration of an anti-cancer chemotherapeutic.  Traditionally, the effects of DOX 
chemotherapy have been examined extensively on the heart and tumor with very little 
attention on skeletal muscle.  The summation of restricted mTOR activity and upregulated 
proteolytic pathways are most likely responsible for the imbalance between protein 
synthesis and degradation, overwhelmingly favoring protein degradation.  Depressed 
protein synthesis and loss of skeletal muscle mass this is a hallmark characteristic attributed 
to cachexia, a muscle wasting pathology and significant factor in the high mortality rate of 
cancer patients.  This may have serious clinical implications where multiple doses of DOX 
chemotherapy administerered in a typical treatment regimen may accelerate the onset of 
cachexia and exacerbate the pathology. This study provides important insight into the 
possible mechanisms involved in the health and maintenance of skeletal muscle integrity 
following DOX chemotherapy and presents a substantial foundation for future studies 
focused on reducing skeletal muscle damage and recovery by targetting amino acid 
metabolism. 
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11.7  Tables 
 
Table 1.  Arterial plasma amino acid concentrations. 
Amino 
Acids 
Dose Timepoint 
 (mg/kg) ctrl 24 48 72 96 120 144 168 192 
Asp 1.5 12.5±0.6 175±31*† 230±44*† 195±10*† 298±24*† 195±27* 183±10*† 255±25*† 252±19*† 
 4.5 12.5±0.6 103±5*† 102±3*† 100±10*† 135±23*† 138±14* 107±5*† 140±12*† 140±7*† 
Ser 1.5 2.5±0.3 52±12* 39±7†* 23±3 30±4* 26±5* 24±3 25±3* 31±3†* 
 4.5 2.5±0.3 37±1* 15±1†* 18±4* 25±4* 20±1* 15±3* 20±3* 21±1†* 
Glu 1.5 0.05±0.01 194±42† 354±83*† 311±30*† 505±80*† 249±35*† 261±24*† 454±79*† 389±41*† 
 4.5 0.05±0.01 65±10*† 94±23*† 81±13*† 68±6*† 143±30*† 77±8*† 119±12*† 76±7*† 
Gly 1.5 11.8±0.7 135±24* 171±37†* 154±23†* 217±16†* 127±23* 94±4 155±16†* 133±12†* 
 4.5 11.8±0.7 87±7* 64±12† 76±12†* 106±27†* 84±13* 75±10* 69±10†* 80±11†* 
His 1.5 9.4±0.6 211±30*† 263±24*† 237±6*† 313±24*† 235±31*† 256±36*† 306±27*† 287±20*† 
 4.5 9.4±0.6 100±21*† 38±7† 92±12*† 134±11*† 148±16*† 121±5*† 144±10*† 48±6† 
Arg 1.5 8.7±0.7 60±13* 82±8*† 67±4*† 87±9*† 63±9* 72±14* 79±17* 96±4*† 
 4.5 8.7±0.7 36±2* 34±3*† 36±5*† 36±3*† 47±6* 48±5* 45±4* 44±5*† 
Thr 1.5 15.2±0.7 268±38* 306±28†* 308±14*† 381±34*† 300±41*† 354±51*† 384±15*† 369±26*† 
 4.5 15.2±0.7 185±10* 161±15†* 137±15*† 182±30*† 182±17*† 163±15*† 182±9*† 189±7*† 
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Ala 1.5 44.1±2.8 262±40*† 320±29*† 247±8*† 340±29*† 242±34* 256±16*† 311±21*† 345±28*† 
 4.5 44.1±2.8 152±12*† 139±5*† 149±12*† 156±12*† 200±22* 171±8*† 189±12*† 223±19*† 
Pro 1.5 9.3±0.6 102±16*† 109±11*† 98±5*† 131±13*† 88±11* 91±5*† 120±12*† 129±9*† 
 4.5 9.3±0.6 58±3*† 51±3*† 50±5*† 54±4*† 65±6* 59±7*† 67±4*† 73±3*† 
Cys 1.5 193.3±4.7 8±1* 14±1* 18±3* 8±2* 14±3* 15±3* 20±3†* 14±2* 
 4.5 193.3±4.7 10±1* 14±2* 12±2* 9±3* 13±3* 10±1* 10±1†* 13±1* 
Tyr 1.5 1.5±0.06 38±5*† 51±7*† 43±4*† 49±3*† 34±3* 45±9*† 49±6*† 56±4*† 
 4.5 1.5±0.06 24±2*† 23±3*† 21±3*† 20±2*† 23±4* 17±2*† 23±2*† 22±1*† 
Val 1.5 13.8±0.9 107±16* 133±20* 122±16* 174±25*† 115±17* 151±23*† 172±16*† 179±10*† 
 4.5 13.8±0.9 76±5* 98±11* 79±13* 80±14*† 97±8* 71±4*† 103±5*† 104±4*† 
Met 1.5 1.4±0.04 36±5*† 41±6*† 36±2*† 44±5*† 34±5* 37±5†* 45±4*† 46±2*† 
 4.5 1.4±0.04 24±0.5*† 22±2*† 20±2*† 19±2*† 23±2* 18±2†* 23±1*† 23±1*† 
Lys 1.5 33.2±2 127±14* 155±13* 152±10* 197±26†* 172±14* 180±21* 207±24*† 187±7*† 
 4.5 33.2±2 102±11* 123±10* 124±17* 114±13†* 164±15* 143±7* 131±12*† 135±9*† 
Iso 1.5 6.4±0.4 45±7 65±11* 60±10* 87±14†* 63±8* 79±15*† 91±10*† 93±7*† 
 4.5 6.4±0.4 32±2* 50±6* 39±7* 37±7†* 49±5* 35±2*† 52±3*† 53±2*† 
Leu 1.5 10.7±0.7 77±12* 109±20* 101±16* 142±22*† 106±14* 131±24*† 153±17*† 155±12*† 
 4.5 10.7±0.7 56±4* 83±9* 67±13* 65±13*† 84±7* 60±4*† 86±4*† 87±5*† 
Phe 1.5 1.4±0.05 32±4*† 35±3*† 35±2*† 42±4*† 32±4*† 35±4*† 44±4*† 43±2*† 
 4.5 1.4±0.05 22±1*† 19±2*† 16±1*† 16±1*† 19±2*† 15±1*† 21±2*† 20±0.3*† 
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NH3 1.5 33.1±1.4 34±8 31±4 26±2 38±6 25±2† 23±2 28±1 27±3 
 4.5 33.1±1.4 30±3 25±2 24±2 26±2 32±2† 26±1 30±3 31±3 
EAA 1.5 95±5 930±131*† 1154±107*† 1084±52*† 1346±108*† 1088±120* 1249±175*† 1372±75*† 1396±44*† 
 4.5 95±5 605±40*† 608±52*† 593±77*† 660±80*† 795±72* 611±38*† 765±44*† 667±46*† 
BCAA 1.5 30.9±2 229.6±34*† 307±51* 284±41*† 402±61*† 283±35* 361±62*† 416±42*† 427±29*† 
 4.5 30.9±2 164±11*† 231±26* 185±33*† 181±34*† 231±20* 139±29*† 240±12*† 244±11*† 
All values are means ± SEM.  Concentrations represented in µM concentrations.  * denotes significance compared to control. † 
denotes significance between doses.  
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Table 2.  Interstitial amino acid concentrations   
Amino 
Acids 
Dose Timepoint 
 (mg/kg) ctrl 24 48 72 96 120 144 168 192 
Asp 1.5 33±2 162±9*† 202±16*† 202±13*† 219±16*† 18±1† 20±1† 18±2 16±1 
 4.5 33±2 18±1*† 19±1*† 23±2*† 39±2† 11±1*† 12±1*† 18±1* 18±2* 
Ser 1.5 13±1 73±5*† 59±6*† 60±6*† 75±9*† 2±0.2† 2±0.2† 1±0.1† 2±0.2† 
 4.5 13±1 3±0.4*† 7±1*† 7±1*† 6±1*† 21±3*† 13±1† 14±2† 10±1† 
Glu 1.5 2±0 58±4*† 66±5*† 55±7*† 30±3* 21±2*† 22±2*† 16±2† 13±1 
 4.5 2±0 12±1*† 16±1*† 22±2*† 39±4* 10±1*† 10±1*† 11±1*† 16±2* 
Gly 1.5 46±3 145±8*† 152±11*† 133±9*† 132±9*† 24±1† 26±2† 22±2† 19±1† 
 4.5 46±3 20±1*† 25±2*† 23±2*† 35±2*† 15±2*† 16±1*† 30±2*† 31±3*† 
His 1.5 36±2 139±9*† 161±10*† 133±9*† 132±9*† 28±2† 30±2† 22±2† 19±1† 
 4.5 36±2 20±1*† 25±2*† 23±2*† 35±2† 20±2*† 20±1*† 30±2† 30±3† 
Arg 1.5 47±3 147±7*† 171±10*† 202±15*† 156±13*† 54±3† 63±5† 43±3† 36±3 
 4.5 47±3 44±2† 44±4† 47±6† 61±4† 29±3*† 31±2*† 32±4† 34±4 
Thr 1.5 29±2 120±13*† 171±10*† 38±5† 19±3† 22±2† 25±2† 14±4 20±2 
 4.5 29±2 4±1*† 3±0.5*† 11±1*† 7±1*† 14±2*† 8±1*† 22±3 21±2 
Ala 1.5 64±4 332±19*† 444±31*† 454±42*† 398±34*† 31±2† 42±3† 29±3† 27±2† 
 4.5 64±4 37±3*† 40±3*† 36±3*† 67±5† 17±2*† 24±2*† 35±3*† 47±7*† 
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Pro 1.5 24±1 71±4*† 80±5*† 89±7*† 82±7*† 8±0.5† 11±1† 9±1 9±1 
 4.5 24±1 10±1*† 12±1*† 10±1*† 17±1*† 5±1*† 6±0.4*† 9±1* 10±1* 
Cys 1.5 8±1 24±1*† 27±2*† 28±2*† 20±2*† 3±0.1*† 3±0.2*† 2±0.2*† 2±0.1*† 
 4.5 8±1 3±0.2*† 3±0.2*† 3±0.4*† 4±0.4*† 2±0.3*† 2±0.1*† 5±0.4*† 5±0.5*† 
Tyr 1.5 4±0 16±1*† 15±1*† 14±1*† 13±1*† 2±0.1† 3±0.2† 2±0.2 2±0.1 
 4.5 4±0 3±0.1*† 3±0.3*† 3±0.2*† 4±0.3† 1±0.2*† 2±0.1*† 2±0.3* 2±0.2* 
Val 1.5 27±1 75±3*† 103±8*† 126±10*† 102±11*† 11±1† 14±1† 12±1 11±1 
 4.5 27±1 22±1† 17±1*† 16±2*† 19±1*† 8±1*† 8±0.4*† 12±1* 12±1* 
Met 1.5 3±0 21±1*† 20±1*† 21±2*† 19±2*† 3±0.1† 3±0.2† 2±0.2 2±0.1 
 4.5 3±0 3±0.2† 3±0.2† 3±0.3† 4±0.3† 1±0.2*† 1±0.1*† 3±0.2 2±0.2 
Lys 1.5 66±2 158±9*† 227±14*† 273±24*† 222±18*† 15±1*† 16±1† 16±2 12±1*† 
 4.5 66±2 24±2*† 19±2*† 222±2*† 30±2*† 12±1*† 13±1*† 17±1* 17±2*† 
Iso 1.5 11±1 25±1*† 43±4*† 52±5*† 37±5*† 5±0.3† 6±1† 6±0.5 5±0.3 
 4.5 11±1 10±1† 6±0.4*† 7±1*† 8±1*† 3±0.5*† 4±0.2*† 6±1* 6±1* 
Leu 1.5 19±1 51±2* 79±7* 94±8* 66±7*† 9±0.5* 11±1*† 10±1*† 9±1*† 
 4.5 19±1 17±1* 11±1* 12±2* 14±1*† 6±1* 6±0.3*† 12±1*† 10±1*† 
Phe 1.5 3±0 11±1*† 9±0.5*† 10±1*† 8±1*† 3±0.2† 3±0.2† 2±0.2 2±0.1 
 4.5 3±0 2±0.2*† 3±0.2† 3±0.2*† 3±0.2† 2±0.2*† 1±0.1*† 2±0.2* 2±0.2* 
NH3 1.5 36±3 156±9*† 215±11*† 254±17*† 107±8*† 22±1† 22±1† 16±1† 13±1† 
 4.5 36±3 22±4*† 26±1*† 19±1*† 26±1*† 15±1*† 15±1*† 28±1*† 23±2*† 
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EAA 1.5 195±8 601±35*† 812±45*† 738±55*† 593±47*† 87.1±5.6† 106±8† 75.1±7.8 72.3±3.5† 
 4.5 195±8 100±5*† 87.4±5.8*† 92.8±8.3*† 117±6*† 64.5±7.8*† 55.9±4*† 100±9* 93.7±9.5*† 
BCAA 1.5 57.3±2.6 151±7*† 225±18*† 272±23*† 204±24*† 24±1.4† 40±2.8† 26.7±2.6 24.7±1.4 
 4.5 57.3±2.6 48.3±2.8† 34.3±2.2*† 34.9±4.6*† 40.1±2.7*† 17.2±2.2*† 17.3±0.9*† 30.6±3.2* 28.1±2.7* 
All values are means ± SEM.  Concentrations represented in µM concentrations.  * denotes significance compared to control. † 
denotes significance between doses.  
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Table 3.  Intracellular amino acids in the medial gastrocnemius. 
Amino 
Acids 
Dose Time post-injection (in hours) 
 (mg/kg) ctrl 24 48 72 96 120 144 168 192 
Asp 1.5 0.19±0.01 0.28±0.05 0.63±0.09* 0.78±0.2* 0.99±0.05*† 0.67±0.1*† 0.71±0.1*† 0.64±0.08*† 0.53±0.05 
 4.5 0.19±0.01 0.43±0.07 0.64±0.13* 0.65±0.06* 0.71±0.07*† 0.68±0.09*† 0.38±0.03† 0.28±0.04† 0.4±0.05 
Ser 1.5 0.35±0.04 0.33±0.05 0.82±0.18 0.73±0.07 0.69±0.04 0.55±0.10 1.16±0.35*† 0.44±0.03† 0.86±0.18 
 4.5 0.35±0.04 0.56±0.11 0.77±0.21* 0.53±0.05 0.57±0.05 0.37±0.09 0.29±0.05† 0.29±0.04† 0.57±0.08 
Glu 1.5 0.03±0.01 0.15±0.02† 0.27±0.04* 0.45±0.10* 0.47±0.04* 0.46±0.03* 0.47±0.08* 0.38±0.05*† 0.37±0.05* 
 4.5 0.03±0.01 0.32±0.05† 0.29±0.05 0.47±0.07* 0.55±0.1* 0.86±0.19* 0.43±0.05* 0.21±0.02† 0.45±0.04* 
Gly 1.5 0.68±0.04 0.47±0.11† 1.65±0.41 2.22±0.62* 2.96±0.15*† 1.87±0.3* 1.8±0.29 1.63±0.24† 1.82±0.18 
 4.5 0.68±0.04 1.66±0.3*† 1.64±0.31* 2.07±0.23* 2.23±0.24*† 2.07±0.25* 1.24±0.08 0.52±0.06† 1.8±0.22* 
His 1.5 0.21±0.01 0.48±0.08† 1.28±0.26* 1.19±0.20* 1.56±0.12* 1.44±0.29* 1.48±0.27* 1.11±0.17*† 1.0±0.98*† 
 4.5 0.21±0.01 0.79±0.1† 1.69±0.63* 1.17±0.1 1.4±0.17* 1.43±0.23* 0.93±0.05 0.61±0.12† 1.53±0.19*† 
Thr 1.5 0.92±0.02 1.03±0.17† 2.76±0.63 3.82±0.57* 3.84±0.18* 5.33±0.95* 4.40±0.47* 4.11±0.64*† 4.98±0.49* 
 4.5 0.92±0.02 3.35±0.32*† 4.65±0.93* 4.59±0.92* 3.79±0.46* 5.73±0.5* 4.08±0.47* 2.16±0.31† 4.59±0.57* 
Ala 1.5 0.72±0.06 0.9±0.12† 1.6±0.16 2.08±0.57* 2.54±0.19*† 1.28±0.19 1.54±0.14† 1.28±0.17† 1.42±0.21 
 4.5 0.72±0.06 1.81±0.29*† 2.2±0.51* 1.65±0.34 1.47±0.12† 1.49±0.22 0.76±0.07† 0.65±0.1† 1.06±0.07 
Pro 1.5 0.11±0.01 0.08±0.01† 0.18±0.02 0.25±0.06* 0.27±0.02* 0.2±0.01 0.23±0.02*† 0.2±0.02† 0.18±0.02† 
 4.5 0.11±0.01 0.18±0.03† 0.23±0.05* 0.26±0.01* 0.22±0.03* 0.22±0.04* 0.11±0.002† 0.08±0.01† 0.11±0.02† 
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Cys 1.5 0.47±0.02 0.02±0.001*† 0.04±0.004*† n/d n/d n/d n/d n/d n/d 
 4.5 0.47±0.02 0.92±0.14*† 0.67±0.08† 0.38±0.09 n/d n/d n/d n/d n/d 
Tyr 1.5 0.03±0.002 n/d 0.06±0.01† 0.11±0.03* 0.11±0.01* 0.09±0.003* 0.09±0.01*† 0.07±0.01*† 0.09±0.01* 
 4.5 0.03±0.002 n/d 0.17±0.04*† 0.08±0.01 0.1±0.02 0.14±0.02* 0.06±0.01† 0.05±0.01† 0.1±0.01 
Val 1.5 0.12±0.01 0.09±0.01† 0.26±0.03* 0.34±0.06* 0.33±0.05* 0.28±0.03* 0.34±0.03*† 0.31±0.03*† 0.29±0.03* 
 4.5 0.12±0.01 0.2±0.03† 0.42±0.1* 0.29±0.02* 0.26±0.03 0.29±0.02* 0.16±0.01† 0.13±0.02† 0.2±0.03 
Met 1.5 0.03±0.002 0.04±0.001† 0.07±0.01† 0.11±0.03* 0.1±0.01* 0.08±0.01*† 0.09±0.002*† 0.08±0.01*† 0.08±0.01*† 
 4.5 0.03±0.002 0.07±0.01† 0.2±0.04*† 0.1±0.01* 0.1±0.02* 0.11±0.01*† 0.05±0.003† 0.04±0.01† 0.05±0.01† 
Lys 1.5 0.42±0.04 0.27±0.03† 1.39±0.21* 0.94±0.42 1.51±0.21* 1.06±0.08 1.25±0.1*† 1.32±0.15*† 0.8±0.13 
 4.5 0.42±0.04 0.72±0.13† 1.01±0.3 2.22±0.38* 1.21±0.26* 1.0±0.21 0.43±0.04† 0.35±0.01† 0.85±0.09 
Iso 1.5 0.06±0.01 0.05±0.01† 0.14±0.01* 0.18±0.03* 0.16±0.03* 0.14±0.02* 0.18±0.02*† 0.16±0.01*† 0.15±0.02*† 
 4.5 0.06±0.01 0.1±0.02† 0.24±0.06* 0.15±0.01 0.14±0.02 0.17±0.02* 0.08±0.01† 0.07±0.01† 0.08±0.01† 
Leu 1.5 0.14±0.01 0.09±0.01† 0.24±0.02 0.33±0.06* 0.3±0.04* 0.26±0.04 0.31±0.03*† 0.3±0.02*† 0.27±0.03† 
 4.5 0.14±0.01 0.2±0.03† 0.42±0.1* 0.25±0.02 0.23±0.04 0.23±0.02 0.13±0.01† 0.12±0.02† 0.16±0.03† 
NH3 1.5 1.29±0.11 0.35±0.02† 0.71±0.1 2.03±0.78 2.23±0.34† 1.42±0.23† 1.35±0.15† 1.55±0.23† 0.98±0.16 
 4.5 1.29±0.11 1.41±0.19† 1.26±0.26 1.21±0.06 0.86±0.09† 0.77±0.09† 0.61±0.04*† 0.83±0.11† 1.19±0.18 
EAA 1.5 3.14±0.15 4.58±0.8† 11.5±1.4* 16.1±2.3* 17.1±1.0* 18.6±1.6* 16.7±1.2* 15.6±1.1*† 16.4±1.2* 
 4.5 3.14±0.15 13.1±1.4*† 15.7±2.4* 17.8±0.5* 15.3±1.7* 16.2±1.1* 13.4±1.0* 8.0±0.6† 16.5±1.9* 
All values are means ± SEM.  Concentrations represented in mmol/kg dry weight.  * denotes significance compared to control. † 
denotes significance between doses. n/d denotes not detectable.  
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Table 4.  Intracellular amino acids in the plantaris 
Amino 
Acids 
Dose Time post-injection (in hours) 
 (mg/kg) ctrl 24 48 72 96 120 144 168 192 
Asp 1.5 0.32±0.03 0.41±0.08 0.79±0.1* 1.01±0.06* 1.17±.0.12* 1.15±0.08* 0.99±0.1* 0.95±0.07* 1.03±0.13* 
 4.5 0.32±0.02 0.81±0.19 1.29±0.19* 1.07±0.09* 1.31±0.12* 0.95±0.05* 0.78±0.08 0.6±0.15 1.1±0.13* 
Ser 1.5 0.89±0.09 0.99±0.22 1.65±0.39 2.37±0.38* 1.80±0.31 3.24±0.42*† 2.53±0.49*† 2.32±0.28 3.02±0.43* 
 4.5 0.89±0.09 2.44±0.61* 2.7±0.44* 2.64±0.14* 2.0±0.16 1.29±0.11† 1.29±0.2† 1.46±0.39 2.73±0.25* 
Glu 1.5 0.05±0.01 0.32±0.08* 0.31±0.04*† 0.65±0.1* 0.49±0.03*† 0.78±0.03*† 0.59±0.04*† 0.57±0.03* 0.65±0.08*† 
 4.5 0.05±0.01 0.61±0.18* 0.61±0.09*† 0.57±0.05* 0.78±0.09*† 1.05±0.04*† 1.1±0.04*† 0.62±0.16* 1.7±0.2*† 
Gly 1.5 0.27±0.01 0.27±0.05† 0.5±0.07 0.70±0.07* 0.83±0.09* 0.74±0.04*† 0.63±0.05* 0.62±0.03* 0.62±0.09* 
 4.5 0.27±0.01 0.71±0.15*† 0.78±0.14* 0.71±0.08* 0.87±0.06* 0.6±0.05† 0.52±0.04 0.55±0.18 0.91±0.12* 
His 1.5 0.45±0.02 0.7±0.15 1.58±0.22* 2.06±0.2* 2.31±0.25* 2.95±0.19* 2.19±0.15* 1.89±0.16*† 2.21±0.26*† 
 4.5 0.45±0.02 2.0±0.53 4.83±1.83* 2.38±0.21 2.81±0.27 2.51±0.19 2.18±0.13 1.16±0.22† 3.79±0.43*† 
Thr 1.5 0.5±0.03 1.04±0.6 1.31±0.1* 1.83±0.2* 1.65±0.11* 2.53±0.2* 1.93±0.13* 1.88±0.1* 2.0±0.22* 
 4.5 0.5±0.03 2.12±0.52* 2.35±0.45* 2.09±0.17* 2.04±0.16* 2.56±0.23* 2.15±0.12* 1.67±0.45 2.19±0.15* 
Ala 1.5 0.96±0.05 1.18±0.26 1.99±0.11*† 2.49±0.17* 2.73±0.27* 2.06±0.17* 1.83±0.23* 1.89±0.16* 2.09±0.2* 
 4.5 0.96±0.05 2.55±0.53* 3.34±0.53*† 2.88±0.3* 2.22±0.16 1.76±0.09 1.43±0.11 1.24±0.42 2.1±0.29 
Pro 1.5 0.11±0.01 0.12±0.02 0.18±0.02† 0.22±0.02* 0.26±0.03* 0.18±0.01 0.21±0.03* 0.21±0.02*† 0.22±0.03* 
 4.5 0.11±0.01 0.21±0.05 0.37±0.07*† 0.3±0.04* 0.27±0.03* 0.22±0.02 0.15±0.01 0.1±0.03† 0.17±0.02 
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Cys 1.5 0.41±0.01 0.03±0.01*† n/d n/d n/d n/d n/d n/d n/d 
 4.5 0.41±0.01 1.13±0.29*† 3.6±0.33* 0.38±0.04 n/d n/d n/d n/d n/d 
Tyr 1.5 0.03±0.002 n/d 0.06±0.01*† 0.10±0.01* 0.11±0.01* 0.09±0.01*† 0.08±0.01* 0.08±0.01*† 0.09±0.01* 
 4.5 0.03±0.002 n/d 0.15±0.02*† 0.09±0.01* 0.13±0.02* 0.12±0.004*† 0.07±0.01* 0.05±0.01† 0.12±0.01* 
Val 1.5 0.13±0.01 0.13±0.03 0.28±0.03*† 0.34±0.03* 0.32±0.03* 0.29±0.03* 0.32±0.03*† 0.3±0.03*† 0.29±0.03* 
 4.5 0.13±0.01 0.26±0.06 0.5±0.09*† 0.35±0.03* 0.36±0.02* 0.3±0.02* 0.22±0.01† 0.14±0.03† 0.23±0.03 
Met 1.5 0.003±0.002 0.05±0.01 0.07±0.01*† 0.1±0.01* 0.1±0.01*† 0.08±0.01*† 0.08±0.01* 0.08±0.01*† 0.08±0.01* 
 4.5 0.003±0.002 0.97±0.03* 0.16±0.02*† 0.12±0.01* 0.13±0.01*† 0.11±0.01*† 0.07±0.01 0.05±0.01† 0.07±0.01 
Lys 1.5 0.04±0.03 0.42±0.09 1.4±0.16* 1.38±0.21* 1.06±0.1* 1.43±0.19*† 1.52±0.16*† 1.51±0.03*† 1.23±0.14* 
 4.5 0.04±0.03 0.970.25 1.75±0.24* 2.05±0.23* 1.1±0.04* 0.94±0.12† 0.87±0.12† 0.47±0.12† 1.19±0.14* 
Iso 1.5 0.07±0.01 0.07±0.01 0.15±0.01*† 0.19±0.02* 0.17±0.02* 0.15±0.01* 0.17±0.02*† 0.16±0.01*† 0.16±0.02* 
 4.5 0.07±0.02 0.14±0.03 0.29±0.05*† 0.2±0.02* 0.2±0.02* 0.16±0.01 0.12±0.01† 0.08±0.02† 0.13±0.02 
Leu 1.5 0.19±0.01 0.15±0.03 0.29±0.03*† 0.38±0.03* 0.33±0.03* 0.3±0.02* 0.32±0.03*† 0.29±0.01*† 0.31±0.03* 
 4.5 0.19±0.01 0.31±0.08 0.56±0.09*† 0.36±0.04* 0.38±0.04* 0.28±0.02 0.2±0.02† 0.13±0.03† 0.22±0.03 
NH3 1.5 1.12±0.08 0.33±0.02 0.81±0.22† 1.09±0.16 1.66±0.52 0.96±0.11† 0.57±0.05 0.79±0.06 0.53±0.03† 
 4.5 1.12±0.08 1.33±0.33 1.82±0.53† 1.26±0.06 0.91±0.09 0.51±0.013† 0.56±0.03 0.8±0.19 1.07±0.02† 
EAA 1.5 2.9±0.3 6.6±1.4† 12.5±0.8*† 16.5±1.4* 15.9±1.1* 19.8±1.0* 15.2±1.4* 14.1±0.6*† 15.7±1.3*† 
 4.5 2.9±0.3 17.6±4.2*† 19.2±1.6*† 19.0±1.3* 18.2±2.8* 20.0±1.4* 17.3±0.7* 8.2±1.0† 21.7±1.6*† 
All values are means ± SEM.  Concentrations represented in mmol/kg dry weight.  * denotes significance compared to control. † 
denotes significance between doses.  n/d denotes not detectable. 
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Table 5. Intracellular amino acids in the soleus. 
Amino 
Acids 
Dose Time post-injection (in hours) 
 (mg/kg) ctrl 24 48 72 96 120 144 168 192 
Asp 1.5 0.18±0.02 0.21±0.02† 0.79±0.08* 0.89±0.13* 0.99±0.01* 0.63±0.02* 0.84±0.07*† 0.59±0.01*† 0.61±0.07* 
 4.5 0.18±0.02 0.59±0.05*† 0.6±0.05* 0.6±0.06* 0.84±0.11* 0.87±0.17* 0.64±0.04*† 0.29±0.01† 0.5±0.09* 
Ser 1.5 0.43±0.04 0.37±0.05† 1.4±0.3* 1.25±0.13*† 0.93±0.1 0.68±0.03 0.97±0.13† 0.74±0.12† 1.31±0.26* 
 4.5 0.43±0.04 1.28±0.24*† 0.93±0.16 0.8±0.11† 1.12±0.31* 0.55±0.14 0.47±0.04† 0.4±0.07† 0.81±0.08 
Glu 1.5 0.02±0.003 0.13±0.02† 0.32±0.02*† 0.48±0.03*† 0.39±0.05* 0.49±0.03*† 0.52±0.03* 0.34±0.03* 0.4±0.02* 
 4.5 0.02±0.003 0.3±0.01† 0.25±0.02† 0.35±0.04*† 0.43±0.01* 1.05±0.15*† 0.58±0.04* 0.25±0.02 0.61±0.* 
Gly 1.5 0.39±0.02 0.28±0.05† 1.17±0.14* 1.53±0.17*† 1.65±0.1*† 1.20±0.09* 1.56±0.04*† 1.05±0.1*† 1.15±0.13* 
 4.5 0.39±0.02 0.94±0.12*† 0.94±0.1* 1.1±0.09*† 1.12±0.08*† 1.42±0.17* 0.88±0.06† 0.53±0.09† 1.23±0.23* 
His 1.5 0.24±0.02 0.37±0.04† 1.79±0.28* 1.72±0.15*† 1.7±0.14* 1.45±0.03*† 1.89±0.18* 1.17±0.09*† 1.41±0.14* 
 4.5 0.24±0.02 1.23±0.06† 1.93±0.53* 1.26±0.12*† 1.82±0.23* 2.23±0.35*† 1.68±0.14* 0.76±0.09† 1.7±0.09* 
Thr 1.5 0.83±0.03 0.86±0.18† 3.64±0.09* 4.39±0.29* 3.4±0.18* 4.89±0.44*† 4.59±0.21* 3.77±0.25*† 4.51±0.3* 
 4.5 0.83±0.03 3.06±0.58*† 4.09±0.55* 4.26±0.25* 3.55±0.32* 7.25±0.57*† 4.61±0.25* 2.71±0.2*† 4.34±0.11* 
Ala 1.5 0.72±0.05 0.85±0.11† 2.16±0.29* 2.32±0.41* 2.48±0.19*† 1.15±0.06† 1.79±0.15*† 1.08±0.16† 1.42±0.11 
 4.5 0.72±0.05 2.12±0.16*† 1.91±0.2* 1.8±0.28* 1.66±0.26*† 1.75±0.19*† 1.25±0.15† 0.61±0.11† 1.27±0.16 
Pro 1.5 0.1±0.01 0.07±0.01† 0.23±0.03* 0.27±0.03* 0.27±0.01* 0.18±0.01† 0.28±0.02*† 0.21±0.01*† 0.22±0.03*† 
 4.5 0.1±0.01 0.15±0.01† 0.21±0.02* 0.24±0.02* 0.23±0.03* 0.26±0.03*† 0.18±0.01† 0.08±0.004† 0.13±0.02† 
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Cys 1.5 0.48±0.03 0.2±0.001*† n/d n/d n/d n/d n/d n/d n/d 
 4.5 0.48±0.03 1.12±0.12† 1.91±0.36* 0.46±0.07 n/d n/d n/d n/d n/d 
Tyr 1.5 0.03±0.002 n/d 0.08±0.01*† 0.11±0.01*† 0.11±0.01* 0.09±0.004*† 0.11±0.01* 0.07±0.004*† 0.07±0.01*† 
 4.5 0.03±0.002 n/d 0.16±0.01*† 0.08±0.01*† 0.1±0.01* 0.16±0.01*† 0.1±0.01* 0.05±0.003† 0.1±0.01*† 
Val 1.5 0.11±0.01 0.09±0.01† 0.36±0.04* 0.4±0.02*† 0.33±0.05* 0.27±0.01*† 0.42±0.03*† 0.27±0.01*† 0.24±0.03* 
 4.5 0.11±0.01 0.24±0.02*† 0.37±0.05* 0.29±0.03*† 0.3±0.05* 0.37±0.04*† 0.28±0.03*† 0.15±0.02† 0.2±0.02 
Met 1.5 0.03±0.003 0.04±0.004† 0.09±0.01*† 0.11±0.01* 0.11±0.01* 0.08±0.01*† 0.11±0.01* 0.07±0.003*† 0.07±0.01*† 
 4.5 0.03±0.003 0.09±0.01*† 0.16±0.01*† 0.1±0.01* 0.12±0.01* 0.14±0.01*† 0.1±0.01* 0.05±0.01† 0.05±0.004† 
Lys 1.5 0.39±0.07 0.22±0.02† 1.53±0.14*† 1.59±0.1* 0.97±0.15* 1.01±0.07* 1.55±0.07*† 1.19±0.09*† 0.86±0.05*† 
 4.5 0.39±0.07 0.73±0.09† 0.89±0.07*† 1.71±0.17* 0.69±0.1 1.03±0.17* 0.89±0.14*† 0.39±0.03† 0.7±0.03† 
Iso 1.5 0.06±0.01 0.04±0.004† 0.19±0.02* 0.21±0.01*† 0.17±0.03* 0.14±0.01*† 0.23±0.02*† 0.14±0.003*† 0.15±0.01*† 
 4.5 0.06±0.01 0.12±0.01† 0.22±0.03* 0.16±0.02*† 0.16±0.03* 0.2±0.02*† 0.15±0.02*† 0.08±0.01† 0.1±0.01† 
Leu 1.5 0.15±0.01 0.09±0.01† 0.34±0.03* 0.39±0.02*† 0.32±0.05* 0.25±0.01* 0.41±0.03*† 0.25±0.01*† 0.26±0.02*† 
 4.5 0.15±0.01 0.27±0.03*† 0.39±0.05* 0.26±0.02† 0.27±0.04 0.31±0.03* 0.25±0.03† 0.13±0.01† 0.17±0.02† 
NH3 1.5 1.38±0.12 0.36±0.06*† 0.92±0.04*† 1.54±0.15 1.05±0.09 1.06±0.04 1.3±0.1 0.67±0.05*† 0.66±0.04*† 
 4.5 1.38±0.12 1.69±0.29† 1.94±0.21† 1.57±0.14 1.05±0.11 1.13±0.17 1.14±0.09 1.02±0.11† 1.65±0.08† 
EAA 1.5 3.4±0.1 5.1±0.7† 18.8±0.4* 21.1±0.6* 17.9±1.1* 19.1±0.7*† 20.7±0.5* 15.2±0.4*† 17.6±0.6* 
 4.5 3.4±0.1 14.2±3.1*† 18.1±2.0* 18.5±1.1* 18.3±1.4* 29.8±2.8*† 21.0±0.7* 9.4±0.8† 18.9±0.7* 
All values are means ± SEM.  Concentrations represented in mmol/kg dry weight.  * denotes significance compared to control. † 
denotes significance between doses.  n/d denotes not detectable.
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CHAPTER V 
 
 
12.  Discussion and Conclusion 
 
It is well accepted that the health and maintenance of skeletal muscle in cancer patients is 
clinically important; however, the effect of anti-cancer chemotherapy on skeletal muscle is poorly 
understood.  Le Bricon et al. (Le Bricon, Gugins, Cynober, & Baracos, 1995) have reported that 
various chemotherapeutic agents (cyclophosphamide, cisplatinum, methotrexate and 5-
fluorouracil) caused a transient weight loss as well as a drug-specific negative nitrogen balance in 
patients.  Additionally, Damrauer et al. (S Damrauer et al., 2008) and Klose et al. (Klose et al., 
2016) have noted that muscle wasting persisted after the reduction of the tumor burden and that 
cisplatin chemotherapy treatment frequently exacerbated the onset of cachexia.  These reports 
suggest that chemotherapeutic agents disrupt metabolic pathways which are responsible for the 
health and preservation of the muscle.  It also appears that these effects occur in concert with the 
drug’s anti-tumor activity.  However, it should be noted that in the aforementioned studies, the 
amount of drug in the muscle was not quantified nor was the retention of the drug in the tissue 
determined.  It is evident that cancer chemotherapeutic agents affect healthy skeletal muscle; 
however, the accumulation of drug in the tissue and the possible sequestering of drug in skeletal 
muscle has not been investigated.  This thesis highlights the role that skeletal muscle plays in DOX 
chemotherapy and the reciprocal effect that this drug has on the tissue.   
In this thesis, a single low dose of DOX was used to minimize the drug-induced risk of 
cardiotoxicity by remaining below the reported threshold of cardiotoxicity.  Previous studies have 
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utilized a variety of concentrations and treatment regimens documenting significant 
cardiomyocyte damage.  Iqbal et al. (Iqbal et al., 2008) administered a single 20 mg/kg dose i.p. 
and observed the induction of acute cardiotoxicity after 48 hours and up to 7 days post 
administration.  A study by Nagi et al. (Nagi & Mansour, 2000) reported that a single dose of 15 
mg/kg i.p. induced cardiotoxicity after 24 and 48 hours and Jensen et al. (Jensen et al., 1984) noted 
that a 10 mg/kg or less total dosage did not cause cardiac failure.  Arola et al. (Arola et al., 2000) 
reported minor cardiomyocyte apoptosis after 3 days following the injection of 1.5 mg/kg and 5 
mg/kg, although it remains unclear whether this significantly altered cardiac performance.  The 
concentrations of 1.5 mg/kg and 4.5 mg/kg used in this thesis provided a dose-related experimental 
contrast while minimizing the drug-induced risk of cardiac dysfunction associated with the higher 
doses.  Furthermore, the aforementioned studies, as well as those employing cumulative doses 
(Guerra et al., 2005; Teraoka et al., 2000) focused on the long term effects of DOX in 
cardiomyocytes where little attention has been given to the early stages of DOX accumulation in 
skeletal muscle.  As such, this thesis investigated the effects of DOX on skeletal muscle every 24 
hours up to 192 hours.  This time frame allowed for the examination of the acute effects of DOX 
accumulation on skeletal muscle as well as the dynamic interaction between the circulation and 
the interstitial space within skeletal muscle.  A highlight of this thesis is the novel finding that a 
single low dose administration of DOX caused a persistent and significant accumulation of the 
drug in skeletal muscle throughout the entire timeline of the experiment (8 days).  Passive diffusion 
of the drug into the tissue alone cannot explain the magnitude of increase of drug in the tissue 
when compared to its concentration in the circulation and in the interstitial space.   
Further support for the rational for the accumulation of Dox can be found in the fact that 
in addition to the nuclei-rich characteristic of skeletal muscle, it is also rich in mitochondria and 
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mitochondrial DNA.  The binding of DOX to DNA, mitochondrial DNA and its high affinity for 
cardiolipin would explain the sequestering of drug in the tissue beyond that of concentrations 
resulting from passive diffusion into the cell.  As skeletal muscle represents the largest organ in 
the human body, the sequestering of DOX in the tissue greatly decreases the systemic availability 
of the drug intended for the tumor.  This effectively reduces the therapeutic impact of the drug 
prompting the need for repeated doses.  This presents an important clinical paradox; the repeated 
administration of the drug increases the exposure of the tumor to the chemotherapeutic agent while 
the intrinsic nature of DOX consequently increases accumulation of the drug in skeletal muscle, 
exacerbating the detrimental effects of the preceding dose.  This prolonged accumulation of DOX 
in the muscle may lead to wasting of the tissue ultimately progressing to a cachectic condition. 
A single low-dose administration of DOX, as shown in Chapter IV, caused a remarkable 3-
4 fold increase in the intramuscular total amino acid pool.  The overall net change of amino acids 
in the tissue is a key indicator of the synthesis or degradation state of proteins in the muscle.  The 
reported increase in total amino acids strongly indicates that the rate of protein breakdown in the 
tissue was greater than that of synthesis.  This is consistent with results reported by Hellin et al. 
(Hellin, Calmant, Gielen, Bours, & Merville, 1998) who has noted that daunomycin, an 
anthracycline similar to DOX, was a potent inducer of NF-κB transcription factors in a colon 
carcinoma cell line.  In addition to its role in reducing tumor cell sensitivity to chemotherapy by 
inhibiting the apoptotic response (Camp et al., 2004; J. C. Cusack, Jr. et al., 2001), the upregulation 
of NF-κB has been shown to cause severe skeletal muscle wasting (Cai et al., 2004; Guttridge, 
Mayo, Madrid, Wang, & Baldwin, 2000; Hunter & Kandarian, 2004).  The potential increase of 
NF-κB as a result of the accumulation of DOX in the muscle has been discussed in Chapter IV, 
where the increase in iNOS activity may be indicative of NF-κB upregulation.  Taken together, the 
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persistent accumulation of a single dose of DOX in the muscle, the possible upregulation of NF-
κB transcription factors as reported by Hellin et al. in addition to the regulatory mechanisms of 
protein synthesis potentially affected by DOX discussed in Chapter IV, this thesis establishes the 
potent myotoxicity of DOX.  The resulting decrease in muscular integrity and potential loss of 
muscle mass, following DOX chemotherapeutic treatment, is of significant importance in cancer 
patients receiving chemotherapy as it reduces the effectiveness of the treatment, affects the quality 
of life of the patient and prolongs the recovery process following the cessation of treatment.  More 
importantly, however is the loss of muscle mass and integrity which is indicative of the early onset 
of cachexia.   
The accumulation and impact of DOX was not limited to the intracellular compartment of 
the tissue.  The study of the interstitial space by way of the microdialysis technique revealed that 
a static pool of DOX was established in the interstitial space following the administration of a 
single dose of DOX.  The rate of appearance of DOX in the interstitial space from the vasculature 
appeared to be matched by the rate of disappearance of the drug from the interstitial space into 
skeletal muscle.  This formed a dynamic equilibrium resulting in a no net accumulation of DOX 
in the interstitial compartment.  The concentration of DOX in the IC was greater than that of the 
ISS suggesting that despite its ability to passively diffuse through the cellular membrane, it was 
retained in the cell.  This is further indication of the strong affinity of DOX to base pairs of the 
DNA as well as other molecules such as cardiolipin found in the mitochondria (as discussed in 
Chapter II).  Additionally, the use of microdialysis helped clarify a confounding result in the acute 
removal of DOX from the tissue into the vasculature by identifying a concurrent increase in 
interstitial nitric oxide concentrations.  This indicates that the increase in perfusion of the tissue 
mediated by local vasodilatory mechanisms play an important role in the removal of the drug from 
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the tissue and back into the circulation.  Furthermore, microdialysis revealed a possible dose-
related effect of DOX on amino acid transport mechanisms from the skeletal muscle compartment 
into the vasculature.  The application of the microdialysis technique to study the interstitial space 
has proven to be a unique and powerful analytical tool in its ability to help elucidate the delivery 
kinetics of anti-cancer drugs in the tissue as well as provide insight into the local mechanisms 
affected by chemotherapy drugs.   
The study of DOX and cardiomyocyte toxicity has deservedly received much of the focus 
of DOX-related research.  As a vital organ it is imperative to conduct research to better understand 
and minimize cardiotoxicity for the benefit of the cancer patient receiving treatment.  With this 
objective in mind, it is equally imperative to acknowledge the role that skeletal muscle plays in 
DOX bioavailability and the ability of the drug to overwhelmingly activate protein degradation 
contributing to the onset of cachexia.  Further elucidation of these relationships would greatly 
improve the effectiveness of the drug, the health of the patient undergoing treatment and ultimately 
favor a positive prognosis. 
In conclusion, the major contributions of this thesis include the quantification of a single 
dose of Doxorubicin in skeletal muscle.  In addition, the accumulatin of intramuscular DOX 
resulted in significant protein degradation and demonstrates for the first time the adverse effect of 
this drug on Skeleltal muscle health and maintenance.  In closing, these studies helped to better 
understand the relationship between chemotherapy and skeletal muscle and represents a major 
contribution to the field.   
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13.  Limitations and Future Directions 
 
One inherent limiatation to the studies performed in this thesis was due to  sample size and 
allocation which resulted in  analytical constraints.  For example, it would have been beneficial to 
be able to perform fiber type analysis of the excised skeletal muscle groups, which would have 
allowed for greater insight into the potential role that the fiber type differences may play in the 
accumulation of DOX in skeletal muscle.  Furthermore, as the samples were collected under basal 
metabolic conditions (the samples were collected while animals were under aneasthesia), 
concurrent sampling during the electrical stimulation of the muscle would provide even greater 
insight on the effects that increased metabolic demand and increased blood flow would have had 
on the accumulation of the  drug in the tissue.  This thesis presents a substantial foundation for 
future studies focused on reducing skeletal muscle damage as a result of DOX chemotherapy.  As 
noted in Study 1 (Chapter II), the presence of drug in the tissue persisted up to 8 days following a 
single treatment, however the length of time that the drug remains sequestered in the tissue has yet 
to be determined.  The natural progression of the studies presented in this thesis is to utilize a 
multiple treatment experimental design.  As DOX is already sequestered in skeletal muscle as a 
result of the initial administration, subsequent doses may or may not elicit the same biphasic 
accumulation response in the tissue.  Additionally, the subsequent administrations of drug may 
prolong the amount of time that the drug is sequestered in the tissue which may lead to cytotoxic 
effects that last beyond the cessation of the chemotherapeutic regimen.  Furthermore, it is of 
particular clinical interest to determine whether repeated doses will induce the same degree of 
increase in amino acids as noted in Study 3 (Chapter IV).  Finally, the next logical step is to move 
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into a xenograft model to determine weather the result of drug administration on skeletal muscle 
reported in this thesis are affected by the presence of a tumor in the system. 
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